

# Competition between histone and transcription factor binding regulates the onset of transcription in zebrafish embryos

Shai R. Joseph<sup>1</sup>, Máté Pálffy<sup>1</sup>, Lennart Hilbert<sup>1,2,3</sup>, Mukesh Kumar<sup>1</sup>, Jens Karschau<sup>3</sup>, Vasily Zaburdaev<sup>2,3</sup>, Andrej Shevchenko<sup>1</sup>, and Nadine L. Vastenhouw<sup>1#</sup>

<sup>1</sup>Max Planck Institute of Molecular Cell Biology and Genetics, <sup>2</sup>Center for Systems Biology Dresden, Pfotenhauerstraße 108, D-01307 Dresden, Germany, <sup>3</sup>Max Planck Institute for the Physics of Complex Systems, Nöthnitzerstraße 38, D-01187 Dresden, Germany <sup>#</sup>Corresponding author

Email: [vastenhouw@mpi-cbg.de](mailto:vastenhouw@mpi-cbg.de)

## SUMMARY

Upon fertilization, the genome of animal embryos remains transcriptionally inactive until the maternal-to-zygotic transition. At this time, the embryo takes control of its development and transcription begins. How the onset of zygotic transcription is regulated remains unclear. Here, we show that a dynamic competition for DNA binding between nucleosome-forming histones and transcription factors regulates zebrafish genome activation. Taking a quantitative approach, we found that the concentration of non-DNA bound core histones sets the time for the onset of transcription. The reduction in nuclear histone concentration that coincides with genome activation does not affect nucleosome density on DNA, but allows transcription factors to compete successfully for DNA binding. In agreement with this, transcription factor binding is sensitive to histone levels and the concentration of transcription factors also affects the time of transcription. Our results demonstrate that the relative levels of histones and transcription factors regulate the onset of transcription in the embryo.

## INTRODUCTION

In many organisms, early embryonic development is directed exclusively by maternal products that are deposited into the female gamete during oogenesis. Following the clearance of a subset of these products (Yartseva and Giraldez, 2015), transcription is initiated and the zygotic genome acquires developmental control (Blythe and Wieschaus, 2015a; Harrison and Eisen, 2015; Lee et al., 2014; Tadros and Lipshitz, 2009). This handover is referred to as the maternal-to-zygotic transition and the onset of transcription is called zygotic genome activation (ZGA). The absolute time and number of cell cycles required before the first transcripts can be detected is species specific (Tadros and Lipshitz, 2009). Additionally, from one gene to another the timing of transcriptional activation varies (Aanes et al., 2011; Collart et al., 2014; Harvey et al., 2013; Heyn et al., 2014; Lott et al., 2011; Owens et al., 2016; Pauli et al., 2012; Sandler and Stathopoulos, 2016; Tan et al., 2013). In fact, for some genes the first zygotic transcripts can be detected several cell cycles before the stage that is traditionally defined as the time point of ZGA (De Renzis et al., 2007; Heyn et al., 2014; Skirkanich et al., 2011; Yang, 2002). In spite of the progress made, it remains unclear how the onset of transcription in embryos is temporally regulated.

Several lines of evidence suggest that the absence of transcription during early embryonic development could be due to limited levels of transcription factors (Almouzni and Wolffe, 1995; Veenstra et al., 1999). In this scenario, transcriptional activation would occur once a threshold level of these factors is reached. For example, experiments that used the transcriptional activity of injected plasmids as a read-out revealed that an increase in the

amount of the potent, heterologous, transcriptional activator GAL4-VP16 can overcome transcriptional repression of its target gene in the early embryo (Almouzni and Wolffe, 1995). However, it remained unclear whether limited levels of transcription factors contribute to the absence of endogenous transcription in early embryos. Additional support for the limited machinery model came from work showing that an increase in the concentration of the general transcription factor TBP can cause premature transcription from an injected – and incompletely chromatinized – DNA template in *Xenopus* embryos. This effect was maintained only when non-specific DNA was added to titrate chromatin assembly (Almouzni and Wolffe, 1995; Veenstra et al., 1999). These results suggested that low TBP levels may play a role in the absence of transcription during the early stages of *Xenopus* development, but that increasing TBP alone is not sufficient to cause sustained premature transcription. During the cleavage stages of *Xenopus* development, TBP levels increase due to translation, which suggests that TBP levels might contribute to the timely activation of transcription during ZGA (Veenstra et al., 1999). Transcription factors have recently been identified that are required for the activation of the first zygotically expressed genes in *Drosophila* (Zelda) and zebrafish (Pou5f3, Sox19b, Nanog) (Harrison et al., 2011; Lee et al., 2013; Leichsenring et al., 2013; Liang et al., 2008; Nien et al., 2011). RNA for these factors is maternally provided and their levels increase due to translation during the early cell cycles. This suggests the possibility that an increase in the concentration of these transcription factors might contribute to the shift from transcriptional repression to transcriptional activity. Although transcription factors levels clearly influence transcriptional activity during early embryogenesis, there is evidence to show that the transcriptional machinery is operational prior to ZGA (Dekens

et al., 2003; Lu et al., 2009; Newport and Kirschner, 1982b; 1982a; Prioleau et al., 1994) (see below). Thus, the timing of ZGA cannot be solely explained by a requirement to reach a threshold level of transcriptional activators.

The finding that a premature increase in the number of nuclei or the amount of DNA resulted in premature transcription of injected plasmids in *Xenopus* embryos suggested that the transcriptional machinery is fully functional prior to genome activation and led to the excess repressor model (Newport and Kirschner, 1982). This model postulates that a transcriptional repressor is titrated by binding to the exponentially increasing amount of genomic DNA, until it is depleted first from the soluble fraction, and then from DNA, to allow for the onset of transcription. Related studies in zebrafish and *Drosophila* have provided further evidence for this model. Endogenous transcription is initiated earlier in zebrafish embryos that accumulate DNA due to a defect in chromosome segregation (Dekens et al., 2003), and transcription is delayed in haploid *Drosophila* embryos compared to diploid embryos, albeit not for all genes (Lu et al., 2009). The excess repressor model predicts that the repressor is present in large excess, at relatively stable levels while the genome is inactive, and can bind DNA with high affinity. Core histones fulfill these criteria (Adamson and Woodland, 1974; Woodland and Adamson, 1977). Moreover, when bound to DNA in the form of nucleosomes, histones can affect DNA accessibility for DNA binding proteins. To date, two key studies have investigated the role of core histones in the temporal regulation of zygotic transcription in *Xenopus* embryos (Almouzni and Wolffe, 1995; Amodeo et al., 2015). Experiments that used the transcriptional activity of injected plasmids as a read-out revealed that premature

transcription caused by an excess of non-specific DNA can be negated by the addition of histones (Almouzni and Wolffe, 1995). More recently, the level of histones H3/H4 was shown to regulate the level of transcription in *Xenopus* egg extract and H3 was suggested to play a similar role in the embryo (Amodeo et al., 2015). Taken together, these results support the idea that histones play a role in regulating the timing of zygotic transcription.

If histones function as repressors according to the original excess repressor model, it would be predicted that a substantial reduction of the histone-density on DNA would cause the onset of transcription (Amodeo et al., 2015; Newport and Kirschner, 1982a). However, while such a scenario might be possible for typical sequence-specific repressors of transcription, it is unlikely for histones. Histones assemble into histone octamers on DNA to form nucleosomes, the basic building blocks of chromatin. Thus, random depletion of nucleosomes from DNA would severely compromise the integrity of chromatin structure. Taken together, there is support for the idea that histone levels play a role in regulating the timing of zygotic transcription, but it remains unclear how this would mechanistically work. Furthermore, the observation that both activator and histone levels play a role in shifting the balance between repression and activation at genome activation remains to be clarified.

Here, we analyze the onset of zygotic transcription in zebrafish embryos. With a quantitative approach, we show that the concentration of non-DNA bound histones determines the timing of zygotic transcription and that all four core histones are required for this effect. The reduction in nuclear histone concentration that coincides with genome

activation does not result in a significant change in nucleosome density, but rather allows transcription factors to successfully compete for DNA binding. In agreement with this, the association of transcription factors with the genome is sensitive to histone levels, and changing the concentration of transcription factors also affects the time of transcription. Our results show that transcription is regulated by a dynamic competition for DNA binding between histones and transcription factors. Transcription begins when the concentration of non-DNA bound histones in the nucleus has sufficiently dropped so that the transcriptional machinery can outcompete histones for binding to DNA.

## RESULTS

In zebrafish, zygotic transcription starts ~3 hours post fertilization, around the tenth cell division (Aanes et al., 2011; Harvey et al., 2013; Heyn et al., 2014; Kane and Kimmel, 1993; Pauli et al., 2012) (Figure 1A). To analyze the onset of transcription in the embryo in detail, we identified six genes that are not maternally provided and that have previously been shown to be activated at the onset of genome activation (Aanes et al., 2011; Pauli et al., 2012) (Figure 1-figure supplement 1A). At the 1000-cell (1K) stage, transcripts can be detected, especially when choosing late stage embryos (Figure 1B). Thus, to clearly distinguish between transcription being off and on, we analyzed early 1K and (mid) high stage embryos. Using this approach, analysis by qPCR allowed us to detect consistent induction of these genes at high stage (Figure 1B and figure 1-supplement 1B). We will refer to the stages before and after induction as before and following genome activation. To relate the onset of transcription to the number of cells present in the embryo, we next counted the number of cells in embryos ranging from 1K

to dome stage. We imaged DAPI-stained nuclei on a 2-photon microscope and counted them using the software Imaris (Figure 1C). Using nuclei as a proxy for cell number, we obtained counts that agreed with numbers of cells per embryo obtained by others for 1K (Keller et al., 2008). In contrast, our cell count for high stage, for example, was slightly higher (1900 vs 1800) (Keller et al., 2008), which is consistent with the later high stage which we analyzed (Figure 1D and Figure 1—source data 1). We conclude that the set of genes we selected is robustly induced at high stage, when embryos contain ~1900 cells, and thus represent a reliable system to analyze the onset of zygotic transcription during embryogenesis.

### ***Increasing the levels of all core histones delays onset transcription and gastrulation***

Experiments in *Xenopus* embryos led to the hypothesis that histone levels regulate the onset of zygotic transcription (Almouzni and Wolffe, 1995; Amodeo et al., 2015). To analyze whether in zebrafish, histones are potential candidates to be excess repressors, we analyzed the relative levels of the core histones—H3, H4, H2A and H2B—by Western blot. We found that they are present at relatively stable amounts from 8-cell to 1K stage (Figure 1E). Assuming that at 1K stage there are sufficient histones to wrap all genomes into chromatin, this suggests that histones are in excess relative to the amount of DNA during the earlier stages. Thus, histones could function as excess repressors of the zygotic genome in zebrafish.

If histones function as excess repressors in zebrafish embryos, it would be predicted that their level would affect the onset of transcription. To test this, we analyzed the effect of

increasing the amount of histones in the embryo on the timing of transcriptional activation. We injected a stoichiometric mixture of the four core histones (from here on referred to as histone cocktail, HC; see Materials and Methods for more details) into embryos at the 1-cell stage and then analyzed the onset of transcription for the previously characterized set of genes (Figure 2A and 1B). An increase in the amount of histones delayed the onset of transcriptional activation: transcripts were detected at high stage in uninjected embryos, whereas in embryos injected with histone cocktail, transcription was only induced at oblong stage, a complete developmental stage later (Figure 2B and figure 2-figure supplement 1A). Comparison of gene expression levels in uninjected and injected embryos at high stage (when transcripts can consistently be detected in uninjected embryos) revealed that the level of induction is reduced significantly upon injection of the histone cocktail but not upon injection of BSA as a control (Figure 2B and figure 2-figure supplement 1A, bar graphs). Extending the analysis further, a large set of genes in Nanostring analysis confirmed that the effect we observed is general, and not limited to six genes (Figure 2C, Figure 2-figure supplement 2, Figure 2-source data 1). Staging by morphology was corroborated by cell counting, with absolute time between the analyzed stages being constant, confirming that changes in the timing of transcription were not due to effects on cell cycle length or developmental progression (Figure 2-figure supplement 1B). Moreover, the injected histones can be incorporated into chromatin, as indicated by labeling one of them with Cy5 and detecting this label in chromatin when imaging embryos after injection (Figure 2-figure supplement 1C), confirming that they are functional. Together, these data show that an increase in the excess amount of histones in the embryo delays the onset of transcription.

To test whether the effect we observe upon injecting the histone cocktail required an increase in the level of all four core histones, we next removed one histone at a time from the cocktail. The total protein content was kept constant by raising the level of the other three histones. Removing any histone from the histone cocktail impaired the ability of the histone cocktail to delay the onset of transcription (Figure 2D and figure 2-figure supplement 1D). These results show that the injection of basic proteins into the embryo per se does not affect the onset of transcription. Moreover, these results argue that the effect of the histone cocktail relies on increasing the amount of all four histones and suggest that histones exert their repressive effect together.

Since the onset of zygotic transcription is known to be required for gastrulation (Kane et al., 1996; Lee et al., 2013; Zamir et al., 1997), we analyzed the effect of injecting the histone cocktail on the onset of gastrulation. Embryos injected with the histone cocktail initiated gastrulation later than uninjected embryos (Figure 2E). Although there was a delay following injection of BSA, it was significantly shorter than that observed with the histone cocktail and appeared to be a non-specific effect of injection (Figure 2F). Following the onset of gastrulation, embryos appeared to develop normally (Figure 2E, 24 hpf). Removing any histone from the histone cocktail reduced the developmental delay we observed upon injecting the histone cocktail (Figure 2F). We note that the developmental delay in the minus-one histone experiments was not reduced to the level observed for BSA injections. We therefore expect that injecting histones has an additional effect on developmental progression that is independent of the delay in

transcription. We conclude that the delay in transcription as a consequence of increased histone levels causes a delay in the onset of gastrulation.

### ***Decreasing the pool of available histones causes premature transcription***

If the level of histones regulates zygotic genome activation, it can also be predicted that a reduction in histone levels would result in the premature induction of transcription. A large fraction of the histones that is present at the onset of transcription is loaded in the egg already as protein (Figure 1E). Pentraxin 3 is a soluble pattern recognition molecule that has been shown to rapidly and irreversibly bind to the core histones H3 and H4 (Bottazzi et al., 2010; Daigo et al., 2014). We injected mRNA encoding PTX3 fused to RFP, to reduce the pool of available histones H3 and H4 in the zebrafish embryo (Figure 3A). As expected, total levels of H3 and H4 were not affected upon injection of this fusion construct (Figure 3B). Next, we examined if H4 co-precipitated with RFP-tagged PTX3 (Figure 3C). Indeed, this histone associates with PTX3 *in vivo*, suggesting that the injection of PTX3 results in a reduction of the soluble amount of histones H3 and H4 in zebrafish cells. A decrease in the soluble amount of histones caused premature transcription activation: transcripts were detected at early 1K stage, while in the uninjected embryos, transcripts were only detected at mid 1K (Figure 3D and figure 3-figure supplement 1A). We included embryos at mid 1K in this experiment, in order to increase our resolution for detecting changes in transcription. Comparison of gene expression levels in uninjected and *ptx3*-injected embryos at early 1K stage (one time-point prior to when genes are first induced in uninjected embryos) revealed that the level of expression is increased upon injection of *ptx3* mRNA (Figure 3D and figure 3-figure

supplement 1A, bar graphs). A control injection with *rfp* mRNA did not result in co-precipitation with H4 (Figure 3C), nor did it affect the onset of transcription (Figure 3D and figure 3-figure supplement 1A). Staging by morphology was corroborated by cell counting (Figure 3-figure supplement 1B), with absolute time between the analyzed stages being constant. Taken together, our results provide evidence that the level of core histones in the embryo dictates the timing of transcriptional activation.

### ***Onset of transcription coincides with a reduction in nuclear histone concentration***

If histones were to function as excess repressors according to the original excess repressor model, the concentration of non-DNA bound histones would be predicted to decrease during the cleavage stages of development. To test this prediction, we determined the absolute (molar) content and, correspondingly, the number of molecules of core histones in embryos using a quantitative mass spectrometry approach we recently developed (Figure 4A and Materials and Methods for more details). We analyzed embryos ranging from 1-cell to shield stage, when gastrulation is well underway (Figure 4B and Figure 4-source data 1). We observed an increase in the levels of histone protein until 1K stage, after which levels remained reasonably stable until sphere stage. Then a rapid increase was observed, which is most likely the result of translation of zygotically produced histone mRNAs. Knowing the absolute numbers of histones per embryo as well as the calculated number of histones required to wrap a genome (Figure 4B, Figure 4-source data 1), allowed us to derive the number of genomes worth of histones per embryo. From that, we derived the number of excess (non-DNA bound) histones per cell in genomes worth of histones, for embryos ranging from 1-cell to dome stage (Figure 4C

and Materials and Methods for more details). For example, at the 1-cell stage, there are 3098 times more histones per cell than are required to wrap the genome into chromatin. Due to the exponential increase in cell number during cleavage divisions, this number has dropped dramatically at 1K stage (Figure 4C). However, due to the large number of histones that is loaded in the oocyte, as well as the increase in histone level due to translation (Figure 4B), there are still nine genomes worth of non-DNA bound histones per cell. Moreover, because what matters for protein binding kinetics is the concentration, we next calculated the concentration of non-DNA bound histones. Because the cleavage divisions are not accompanied by significant growth (the total animal cap volume increases by 29% from 128-cell to 1K, figure 4-figure supplement 1A), the decreasing number of histones per cell is accompanied by a decreasing cellular volume, and the concentration of non-DNA bound histones in the cell does not change substantially (Figure 4D). Taken together, this shows that during transcription activation there is still a significant amount of non-DNA bound histone and that the overall concentration of non-DNA bound histones in the cell has not decreased by much.

Because transcription takes place in the nucleus, we next wanted to investigate the concentration of non-DNA bound histones in this compartment of the cell. First, we analyzed the dynamics of histone localization by lightsheet microscopy of living embryos (Figure 4-figure supplement 1B and movie 1). As expected, we found a close coordination between the formation of nuclei after cell division and the import of histones from the cytoplasm into the nucleus: during each cell cycle, non-DNA bound histones are concentrated in the nucleus. A direct quantification of non-DNA bound,

endogenous histones in the nucleus is difficult, but by combining lightsheet microscopy measurements of both the nuclear volume fraction and the relative fluorescence intensity of histone H4 in cytoplasm and nucleus with the absolute amount of histone H4 as quantified by mass spectrometry, we were able to calculate the nuclear concentration of non-DNA bound histones from 256-cell to oblong stage (Figure 4E, figure 4-figure supplement 1A and see Materials and Methods for more details). Importantly, our calculations indicate a decrease in the nuclear concentration of non-DNA bound histones at the onset of transcription. In combination with our finding that histone levels determine the timing of transcription, this suggests that a decrease in the concentration of non-DNA bound histones in the nucleus causes the onset of transcription during embryogenesis.

### ***Nucleosome density on DNA is unchanged during genome activation***

We next analyzed whether the decreased concentration of non-DNA bound histones in the nucleus is accompanied by a reduced density of nucleosomes on chromatin. We quantified the amount of histone H2B in the chromatin fraction of embryos ranging from 256-cell to high stage. Comparing the amount of histone H2B between stages revealed that the level of H2B scales with the amount of DNA (Figure 4F and figure 4-figure supplement 1C). This is in agreement with a previous study in which we found that the density of nucleosomes does not significantly change during genome activation (Zhang et al., 2014). Our results reveal that global nucleosome density on DNA does not change during genome activation. Taken together, this suggests that the concentration of non-DNA bound histones in the nucleus determines the timing of transcription without the need for a significant change in global nucleosome density.

### ***A competition model for the onset of transcription***

Our finding that the concentration of histones in the nucleus determines the onset of transcription without a significant change in global nucleosome density on DNA suggests that a simple depletion model cannot explain a role for histone levels in the timing of zygotic transcription. To explain the effect of histone levels on zygotic genome activation, we hypothesized that the transcriptional machinery (for simplicity referred to as transcription factors) competes with nucleosome-forming histones for binding to only a minimal fraction of the total DNA, corresponding to transcription factor binding sites (Figure 4G). In such a model, local substitution of nucleosomes by transcription factors allows for transcription to be activated, but will cause only localized changes in nucleosome positioning, and will barely affect the average nucleosome density. Transcription factors would lose the competition for DNA binding in the presence of an excess of histones (pre-ZGA), whereas a reduction of the concentration of non-DNA bound histones in the nucleus would allow transcription factors to gain access to DNA (approaching ZGA) and initiate transcription (ZGA).

### ***Decreasing transcription factor levels delays the onset of transcription***

If competition between nucleosome-forming histones and the transcriptional machinery determines the onset of transcription, it would be predicted that the levels at which transcription factors are present could also affect the timing of zygotic transcription. To test this, we changed the level of Pou5f3, a transcription factor that has been identified as being required for the activation of a large set of genes during genome activation (Lee et al., 2013; Leichsenring et al., 2013; Onichtchouk et al., 2010). To analyze the effect on

the onset of transcription (Figure 5A), we selected five genes that are activated at the onset of genome activation and that have been identified as Pou5f3 targets (Figure 1-figure supplement 1A) (Onichtchouk et al., 2010).

To reduce the level of Pou5f3, we used a previously characterized morpholino (Burgess et al., 2002) and confirmed its effect by analyzing the morphology of injected embryos and the effect of the morpholino on the translation of injected RNA encoding Pou5f3 (Figure 5-figure supplement 1A). We verified that the selected Pou5f3-target genes require Pou5f3 for their expression and that other genes do not (Figure 5-figure supplement 1B), and analyzed the effect of a reduction in Pou5f3 levels on the timing of transcription of target genes (Figure 5A). Consistent with our model, a reduction in the amount of Pou5f3 delayed the onset of transcriptional activation: transcripts were detected in the middle of 1K stage in embryos injected with control morpholino, while in the embryos injected with Pou5f3 morpholino, the genes started to be transcribed at high stage (Figure 5B and figure 5-figure supplement 1C). We analyzed embryos at mid 1K in this experiment, because the delay that we observe is weaker than with the histone cocktail. Comparison of gene expression levels in control morpholino and Pou5f3 morpholino-injected embryos at mid 1K (when transcripts can first be detected in control morpholino-injected embryos) revealed that the level of induction is significantly reduced upon injection of Pou5f3 morpholino (Figure 5B and figure 5-figure supplement 1C, bar graphs). Performing similar experiments for two additional transcription factors (Sox19b and FoxH1) revealed that this effect is general, and not specific to Pou5f3 (Figure 5-figure supplement 1D-G). Staging by morphology was corroborated by cell counting with absolute time between the analyzed stages being constant (Figure 5-figure supplement

1H). Together, these data show that a decrease in the level of transcription factors in the embryo delays the onset of transcription of target genes.

### ***Increasing transcription factor levels causes premature transcription***

Next, we analyzed the effect of increasing the level of Pou5f3 on the transcription of the selected Pou5f3 target genes (Figure 5A). We co-injected mRNA coding for Sox19b because it has been shown that Pou5f3 and Sox19b often co-occupy their target genes (Chen et al., 2014; Leichsenring et al., 2013; Onichtchouk et al., 2010). Injecting mRNA encoding these transcription factors resulted in overexpression of both proteins and the expected phenotypes for Pou5f3 overexpression (Figure 5-figure supplement 2A) (Belting et al., 2011). Although Pou5f3 was required for the expression of all genes we selected (Figure 5-figure supplement 1B), Pou5f3 and Sox19b were only sufficient to increase the expression level of *apoeb* and *dusp6* at high stage (Figure 5-figure supplement 2B). In agreement with this observation, overexpression of Pou5f3 and Sox19b resulted in premature expression of *apoeb* and *dusp6*: transcripts were detected at early 1K stage in embryos injected with *pou5f3* and *sox19b*, whereas in the embryos injected with control mRNA, transcripts could be detected only at high stage (Figure 5C). Comparison of gene expression levels in control, and *pou5f3* and *sox19b* mRNA-injected embryos at early 1K stage (one time-point prior to when genes are first induced in uninjected embryos) revealed that the level of expression is increased significantly upon injection of *pou5f3* and *sox19b* mRNA for *apoeb* and *dusp6* (Figure 5C, bar graphs). Such an effect on the timing of transcription was not observed for the other genes (Figure 5-figure supplement 2C). Staging by morphology was corroborated by cell counting,

with absolute time between the analyzed stages being constant, (Figure 5-figure supplement 2D). These experiments show that an increase in the level of Pou5f3 and Sox19b in the embryo can cause premature transcription. Taken together, our results show that changing the concentration of endogenous transcription factors can affect the onset of transcription. This is in agreement with our model in which the relative levels of histones and transcription factors determine the onset of transcription.

### ***Transcription factor binding is sensitive to histone levels***

If transcription factors and histones compete for DNA binding, it would be predicted that transcription factor binding is sensitive to histone levels. To directly test competition at the chromatin level, we determined whether the binding of the transcriptional machinery is affected by histone levels. We analyzed the binding of Pou5f3 to its predicted target sites upstream of *apoeb* and *dusp6* by chromatin immunoprecipitation (ChIP) and identified co-precipitated DNA fragments by qPCR (Figure 5D). In embryos that were injected with mRNA encoding both Pou5f3 and Sox19b, we found that the binding of Pou5f3 was readily detected at early 1K stage (Figure 5D, white bars). When the HC was co-injected, binding of the transcription factor was reduced (Figure 5D, gray bars). We expect, but did not test, that nucleosome density is concordantly increased at these binding sites. A control region in genomic DNA did not show any binding of Pou5f3 (Figure 5D). Taken together, this shows that the binding of an endogenous transcription factor is sensitive to the amount of histones present in the embryo.

### ***Experimental evidence for competition using a heterologous transgene***

Our results support a model in which transcription is regulated by the relative levels of histones and transcription factors. Endogenous gene regulation, however, is intrinsically complex, with multiple transcription factors providing input on the same gene, and often there is limited information on the number and strength of activator binding sites. Because this might have affected the results we obtained with endogenous transcription factors and genes (Figure 5), we decided to take advantage of a heterologous system to confirm our results. The integrated inducible transgene TRE:GFP (Figure 6A) contains seven binding sites for tTA-VP16 as well as a CMV promoter, and is strictly dependent on tTA-VP16 for its expression (data not shown). tTA-VP16 was tagged with HA and a protein product was detected at the 1K stage following injection of mRNA (Figure 6-figure supplement 1A). Injection of 5 pg of mRNA encoding the heterologous transcription factor tTA-VP16 resulted in the detection of transcripts at high stage, in accordance with the onset of zygotic transcription of endogenous genes (Figure 6B). Next, we analyzed the transcriptional activity of this transgene upon injection of 300 pg of mRNA encoding tTA-VP16 and we observed that transcripts could be detected at early 1K (Figure 6B). Comparison of gene expression levels at early 1K stage (one stage prior to when genes are first induced in embryos injected with 5 pg of mRNA) in embryos injected with 5 and 300 pg of mRNA revealed that the number of transcripts is increased significantly upon increasing the level of transcription factor (Figure 6B, bar graph). Next, we tested whether an increase in histone levels would negate the effect of high levels of transcription factor. As predicted by the competition model, this increase in transcriptional activity that is observed upon the injection of 300 pg of tTA-VP16 mRNA is lost when the histone cocktail is co-injected (Figure 6C). Finally, we determined

whether the binding of tTA is affected by histone levels. We analyzed the binding of tTA-VP16 to the TRE sites in the transgene by ChIP-qPCR (Figure 6A). We found that upon injecting 300 pg of tTA-VP16 mRNA, the binding of the transcription factor was readily detected at early 1K stage (Figure 6D and figure 6-figure supplement 1B). As expected, binding of the transcription factor was significantly reduced when the HC was co-injected. Control regions within the transgene and in genomic DNA did not show any binding of tTA-VP16 (Figure 6D and figure 6-figure supplement 1B). This shows that the binding of a heterologous transcription factor is sensitive to the amount of histones present in the embryo. These results are in agreement with the results obtained with the endogenous transcription factors (Figure 5). Taken together, our data provide direct evidence for a model in which competition between histones and transcription factors determines the onset of transcription.

## **DISCUSSION**

In this study, we have shown that the concentration of all four core histones determines the onset of transcription in zebrafish embryos by competing with transcription factors for binding to DNA. Upon fertilization, there is a large excess of histones stockpiled in the embryo and transcription starts when the concentration of non-DNA bound histones in the nucleus drops, and the transcriptional machinery gains access to DNA. Thus, the relative concentrations of both histones and transcription factors determine the timing of zygotic genome activation (Figure 4G). Our observations provide, to our knowledge, the first example of a developmental transition in which competition for DNA binding

between histones and transcription factors plays an important role in transcriptional regulation.

***All core histones are important for timing of transcription***

Our observation that histone levels affect the time of transcription onset in zebrafish embryos is in agreement with previous studies that showed a role of histones in the regulation of transcription in early *Xenopus* embryos and extracts (Almouzni and Wolffe, 1995; Amodeo et al., 2015). However, our finding that histones are neither completely depleted from the soluble fraction, nor generally depleted from chromatin, argues against a model in which a global loss of nucleosome density on chromatin causes the onset of transcription (Amodeo et al., 2015). Our work does not exclude the importance of other factors, such as the linker histone H1 (Pérez-Montero et al., 2013), the embryonic form of which is stably present during zebrafish genome activation, but it establishes that core histones themselves function as actual repressors of transcription.

Our discovery that all core histones are required to regulate the onset of transcription suggests that the nucleosome is important for the repressor function of histones. In a previous study, premature transcription of injected plasmids caused by an excess of non-specific DNA was negated by the addition of the four core histones, but histones were not tested separately and it was not clear whether one or more histones were required for the observed effect on transcription (Almouzni and Wolffe, 1995). This left open the possibility that single histones could repress transcriptional activity in the embryo, for example by binding to a transcription factor and preventing it from binding to DNA.

However, our observation that in the embryo all core histones are important for the regulation of transcription would then require all histones to independently take part in this mode of repression. Because this is a very unlikely scenario, we propose that repression takes place close to DNA, where histones are assembled into a histone octamer to form the nucleosome.

### ***Changes in nuclear histone concentration during genome activation***

We propose that genome activation follows a decrease in the concentration of non-DNA bound histones in the nucleus. One possible way to explain the reduction in nuclear histone concentration is the exponential increase in DNA content during the cleavage stages of zebrafish development. Because histones have a high affinity for DNA, an increase in the amount of DNA would titrate out non-DNA bound histones. Several experiments that have indeed shown that changes in DNA content can affect the time of transcription in *Drosophila*, zebrafish and *Xenopus* (Dekens et al., 2003; Lu et al., 2009; Newport and Kirschner, 1982a; Prioleau et al., 1994). Our data suggests that these effects were the result of reducing the concentration of non-DNA bound histones. In zebrafish embryos, the amount of histones is so large that the increase in DNA content leading up to genome activation may contribute only moderately to a decrease in the concentration of non-DNA bound histones in the nucleus.

Another possible explanation for the decrease in nuclear histone concentration is the marked increase in the ratio of nuclear over cytoplasmic volume during the cleavage stages (Figure 4-figure supplement 1A). We suggest that this may limit the capacity of

the nucleus to concentrate histones. The process of nuclear transport has been investigated in great detail (Kim and Elbaum, 2013a; 2013b; Kopito and Elbaum, 2007; 2009) and we can assume that the nuclear envelope can create a certain fold difference in concentrations between the nucleus and cytoplasm. During the initial stages of zebrafish development, the nucleus occupies only a very small fraction of the cell volume (1.1% at 128-cell stage, Figure 4-figure supplement 1A). As a result, when the nucleus concentrates histones up to the maximum fold difference between cytoplasm and nucleus, the cytoplasmic histone concentration is hardly altered. Later in development, when approaching the onset of zygotic transcription, the nucleus takes up a notably larger part of the total cell volume (7.1% at high stage, Figure 4-figure supplement 1A). Now, when histones are imported into the nucleus, the concentration of histones in the cytoplasm noticeably decreases. The nuclear envelope is still able to create approximately the same fold difference of concentrations, but due to the reduced cytoplasmic concentration, the achieved nuclear concentration is not as high as during the initial stages. Thus, in this scenario, the nuclear histone concentration decreases due to the increasing relative nuclear size, which alters the distribution of histones among cellular compartments. It may be expected that the relative increase in nuclear size affects the nuclear concentration of transcription factors as well, and it remains to be seen how the concentration of histones and transcription factors change with respect to each other in order to activate transcription. Experiments recently performed in *Xenopus* showed that changing the size of the nucleus affects the timing of transcription (Jevtić and Levy, 2015), providing further evidence for a role of nuclear size in regulating the onset of transcription.

### ***Competition for DNA binding determines transcription onset***

Our finding that the onset of transcription depends on the concentration of histones, but also on the concentration of transcription factors, is consistent with previous studies that suggested an important role for transcriptional activators in the temporal regulation of zygotic transcription (Almouzni and Wolffe, 1995; Prioleau et al., 1994; Veenstra et al., 1999). Because transcription can be induced prior to the onset of genome activation, both by adding DNA (Dekens et al., 2003; Lu et al., 2009; Newport and Kirschner, 1982a) or removing histones (this study), we suggest that transcription factors required for the onset of transcription are in principle present prior to genome activation. To shift the balance from repression to activation, the relative concentrations of histones and transcription factors need to be changed in favor of transcription factors. This would explain previous observations in *Xenopus*, where the addition of TBP (in combination with adding DNA) or GAL4-VP16 resulted in premature transcription (Almouzni and Wolffe, 1995; Veenstra et al., 1999). Based on our findings, those experiments would have shifted the balance in favor of transcriptional activity, similar to the effect observed when we increased transcription factor levels or decreased histone levels.

Our model in which histones and transcription factors dynamically compete for DNA binding to regulate transcription in the embryo is consistent with the notion that most transcription factors cannot bind DNA when it is wrapped around a nucleosome and thus compete with nucleosomes for DNA access (Almouzni and Wolffe, 1993; Almouzni et al., 1990; Hayes and Wolffe, 1992; Miller and Widom, 2003; Mirny, 2010; Ramachandran and Henikoff, 2016; Raveh-Sadka et al., 2012; Schild-Poulter et al., 1996;

Svaren et al., 1994). Initially, there is a large excess of histones stockpiled in the embryo and transcription starts when the concentration of non-DNA bound histones in the nucleus drops and the transcriptional machinery gains access to DNA. In contrast to a competition model that was previously proposed (Prioleau et al., 1994; 1995), transcription factors do not need to be pre-bound to DNA in order to compete with histones, but rather, they dynamically compete with histones for DNA binding.

Our experiments did not address when competition takes place during the cell cycle. Competition for DNA binding might either occur immediately following replication, on temporarily naked DNA, or following chromatin assembly. Recent studies assessing the nucleosome landscape following replication have revealed that replication-coupled nucleosome assembly initially outcompetes transcription factors for binding to DNA but that chromatin remodeling and phasing of nucleosomes by remodelers and transcription factors occurs rapidly thereafter (Fennessy and Owen-Hughes, 2016; Ramachandran and Henikoff, 2016; Vasseur et al., 2016). Future experiments will determine the details of competition in the early embryo, with its rapid cell cycles and large pool of soluble histones.

To gain further insight in the molecular details of competition that lead up to genome activation, it will be important to determine which factors compete with histones for DNA binding. In theory, the binding of all factors that require access to DNA could be affected by histone levels, suggesting that competition might take place at many levels of transcription regulation: the formation of higher order chromatin structure, chromatin

remodeling, the binding of transcription factors, and the assembly of the basal transcription complex. Our results show that the transcription factors that have been identified to regulate many genes during genome activation in zebrafish (Pou5f3 and Sox19b) (Lee et al., 2013; Leichsenring et al., 2013), as well as FoxH1 and the heterologous transcription factor tTA-VP16, compete with histones for binding to DNA (Figure 5 and 6). In this context it is interesting to note that the transcription factors that have been identified to play a role in genome activation have either been suggested to be pioneer factors (Lee et al., 2013; Leichsenring et al., 2013), or there is indication for such a role because of their homology with mammalian pioneer factors (Lee et al., 2013; Leichsenring et al., 2013; Soufi et al., 2012). Pioneer factors are able to interact with DNA that is nucleosome bound (Zaret and Carroll, 2011). In the context of the competition model, it will be interesting to see whether these factors also have pioneering activity in the early embryo, and how this affects their role in activating transcription in the embryo.

### ***General relevance of competition in development***

The applicability of the competition model might extend well beyond the onset of zygotic transcription in zebrafish. First, given the excess of histones in a large number of species including *Drosophila*, *Xenopus*, and zebrafish (Adamson and Woodland, 1974; Li et al., 2012; Marzluff and Duronio, 2002; Osley, 1991; Vastenhouw et al., 2010; Woodland and Adamson, 1977), it is likely that histone levels play a role in the timing of zygotic transcription across these species. As discussed, in *Xenopus* embryos there is indeed evidence for a role of histone levels in regulating transcriptional activity (Almouzni and

Wolffe, 1995; Amodeo et al., 2015). Additional experiments will be required to determine whether the competition model we propose applies to these and other species. Second, the onset of zygotic transcription in the embryo takes place in the context of the mid-blastula transition and is accompanied by a lengthening of the cell cycle and changes in chromatin structure. Although it had previously been suggested that the rapid cell cycles lacking G1 and G2 phases might interfere with productive transcription during early developmental stages (Collart et al., 2013; Edgar and Schubiger, 1986; Kimelman et al., 1987), it was recently shown that the lengthening of the cell cycle might be a direct consequence of the onset of transcription in *Drosophila* embryos (Blythe and Wieschaus, 2015b). This would suggest that what regulates the onset of zygotic transcription might also dictate the lengthening of the cell cycle. Finally, post-translational modification of histones often requires a chromatin modifying enzyme to bind to DNA, much like transcription factors. Thus, competition is likely to affect the *de novo* modification of histones as well, explaining why many histone modifications are only observed around the onset of zygotic transcription in their temporal profile (Lindeman et al., 2011; Vastenhouw et al., 2010). Importantly, we observe an effect on the timing of transcription by adding unmodified histones. This suggests that post-translational modifications of histones are either downstream of the timing of transcriptional activation, or the enzymes that modify histones are not limiting in the embryo.

The competition model can explain why genome activation is gene specific (Aanes et al., 2011; Collart et al., 2014; Harvey et al., 2013; Heyn et al., 2014; Lott et al., 2011; Owens et al., 2016; Pauli et al., 2012; Sandler and Stathopoulos, 2016; Tan et al., 2013), and

even why the first zygotic transcripts can be detected several cell cycles before the stage that is traditionally defined as the time point of ZGA (De Renzis et al., 2007; Heyn et al., 2014; Skirkanich et al., 2011; Yang, 2002). The sensitivity of genes for a given histone concentration logically depends on their enhancers and the affinity and concentration of the transcription factors that bind to them. In this context, it is interesting to note that many genes that are activated during zebrafish genome activation respond to the same set of transcription factors, which are also the most highly translated transcription factors before genome activation (Lee et al., 2013; Leichsenring et al., 2013). Conversely, the affinity of transcription factors and the number of transcription factor binding sites might provide a mechanism to explain why some genes overcome repression earlier than others (Heyn et al., 2014). Indeed, in *Drosophila*, it has been shown that the number of transcription factor binding sites as well as the level of transcription factors can affect the timing of gene expression (Foo et al., 2014; Harrison et al., 2010).

Recent literature suggests that histone levels might play a role in the regulation of transcription during developmental transitions other than genome activation. In contrast to the situation in early embryos, where histone and DNA levels do not scale, it was generally believed that in somatic cells, histone production is tightly coupled to replication (Nurse, 1983). Recently, however, histone levels have been shown to change during ageing and differentiation (Feser et al., 2010; Hu et al., 2014; Karnavas et al., 2014; O'Sullivan et al., 2010) suggesting that histone levels might not be as tightly coupled to DNA replication as previously thought. Moreover, histone chaperones were identified as inhibitors of reprogramming (Cheloufi et al., 2015; Ishiuchi et al., 2015) and

it was proposed that the lack of histone chaperones facilitates transcription factor binding (Cheloufi et al., 2015). Taken together, these studies might suggest that the availability of histones could play a role in the regulation of transcription during differentiation and reprogramming.

We have shown that the onset of transcription is regulated by a dynamic competition for DNA binding between histones and transcription factors. This suggests that the relative levels of histones and transcription factors in the nucleus determine the time at which transcription begins in the embryo. Future studies will be required to improve our understanding of the molecular mechanism of competition, the regulation of repressor and activator concentrations in the nucleus, and the role of competition during other developmental transitions.

## MATERIALS AND METHODS

### *Zebrafish husbandry and manipulation*

Zebrafish were maintained and raised under standard conditions. Wild-type (TLAB) (WT-TL RRID:ZIRC\_ZL86, WT-AB RRID:ZIRC\_ZL1) and transgenic embryos were dechorionated immediately upon fertilization, synchronized and allowed to develop to the desired stage at 28°C. Stage was determined by morphology and corroborated by cell counting. In terms of absolute time, the time between collected stages around ZGA was consistent between all conditions within an experiment and for all experiments. Histone cocktail and BSA (A9418; Sigma, St. Louis, MO) were injected into the yolk at the 1-cell stage at 22 ng per embryo. Pou5f3 anti-sense morpholino was injected at 6 ng per embryo, together with 1 ng of p53 morpholino (Langheinrich et al., 2002). Sox19b anti-sense morpholino (Okuda et al., 2010) was injected at 2 ng per embryo and FoxH1 anti-sense morpholino (Pei et al., 2007) was injected at 4 ng per embryo, together with 1 ng of p53 morpholino. Dead-end (Weidinger et al., 2003) or control morpholino were injected as a control at the same concentration. Morpholino sequences can be found in Table 1.  $\alpha$  amanitin (A2263; Sigma) was injected at the 1-cell stage at a concentration of 0.2 ng per embryo. 2.8 mg/ml rhodamine-dextran (D3307; Molecular Probes, Eugene, OR) was used as an injection marker for the HC and BSA experiments. For all other injections, 0.1% Phenol red (P0290; Sigma) was injected. Bright-field images of whole embryos were acquired on a Leica M165 C dissecting scope equipped with a Leica MC170 HD camera (Leica, Wetzlar, Germany).

### ***mRNA production and injection***

mRNA was synthesized using the Ambion™ mMACHINE™ SP6 Transcription Kit (AM1430; ThermoFisher Scientific, Waltham, MA). Human PTX3 cDNA was cloned into a pCS2+ vector with a C-terminal RFP. *ptx3-rfp* and *rfp* mRNA were injected into the cell at the 1-cell stage at a concentration of 300 pg per embryo. Zebrafish Pou5f3 and Sox19b cDNA were cloned into a pCS2+ vector containing 2xHA sequences. For gene expression experiments, *pou5f3-2xHA* and *sox19b-2xHA* mRNA were each injected into the cell of 1-cell embryos at 300 pg per embryo. mRNA encoding cytoplasmic *gfp* was injected as a control at 600 pg per embryo. For ChIP-qPCR experiments, *pou5f3-2xHA* and *sox19b-mEos2* mRNA were each injected into the cell of 1-cell embryos at 150 pg per embryo. A subsequent injection of either histone cocktail or mock (histone buffer) into the yolk was carried out. Human H4 cDNA was cloned into a pCS2+ vector with C-terminal sfGFP (50550; addgene, Cambridge, MA) (Olson et al., 2014). mRNA encoding H4-sfGFP was injected into the cell of 1-cell embryos at 240 pg per embryo. tTA-VP16 DNA was cloned into a pCS2+ vector containing 2xHA sequences. mRNA encoding tTA-VP16-2xHA was injected into the cell of 1-cell Tg(TRE:GFP) embryos either at 5 pg or 300 pg per embryo. The combination injection of 300 pg *tTA-VP16-2xHA* mRNA and histone cocktail, involved two subsequent injections into the cell of 1-cell embryos and yolk respectively. The 300 pg *tTA-VP16-2xHA* mRNA only injections also received a secondary mock injection into the yolk.

### ***Quantitative PCR***

Twenty-five embryos per developmental stage were snap frozen in liquid nitrogen. RNeasy Mini Kit (74104; Qiagen, Venlo, the Netherlands) was used to extract RNA. For Tg(TRE:GFP) embryos, contaminating DNA was removed from RNA preparations using the DNA-free™ Kit (AM1906; ThermoFisher Scientific). mRNA was converted to cDNA using the iScript cDNA Synthesis Kit (1708891; Bio-Rad Laboratories, Hercules, CA). SYBR green (AB-1158.; ThermoFisher Scientific) with Rox (R1371; ThermoFisher Scientific; 100 nM) was used as the qPCR master mix. Primers were used at a final concentration of 500 nM and sequences can be found in Table 2. Two or three technical replicates were performed for each sample. Ct values were normalized to the maternally loaded gene *eif4g2a* or input in ChIP-qPCR analysis. Relative mRNA expression levels were calculated via  $1/(2^{-(\text{gene}-eif4g2a)})$ . Fold difference was calculated by dividing the relative mRNA expression level value of the test sample over control.

### ***Staging embryos by cell counting***

Embryos were fixed in 4% formaldehyde in Danieau's solution at 4°C overnight. The next day, embryos were washed with Danieau's solution and then permeabilized with 0.2% Triton X in Danieau's solution for 30 min. Subsequently, embryos were incubated for 10 min in DAPI (1 µg/ml) and then washed several times with Danieau's solution. Embryos were placed in an inverted agarose holder and covered with Danieau's solution for imaging. An upright Zeiss LSM 780 NLO microscope equipped with a coherent Chameleon Vision II infrared laser was used for 2-photon excitation (Carl Zeiss AG, Oberkochen, Germany). DAPI was excited with 780 nm and detected using a non-descanned GaAsP detector (BIG-Module) with BP450/60 or SP485. Samples were

imaged with either a Zeiss W Plan-Apochromat 20x 1.0 or 40x 1.0 dipping objective. Images were acquired using a four tile scan of multiple z-sections (3-3.5  $\mu\text{m}$  steps). Tiles were stitched with the ZEN software (RRID:SCR\_013672, Zeiss). Images were imported into the Imaris software (RRID:SCR\_007370, Bitplane, Belfast, Northern Ireland) and the spot tool was used to calculate cell number.

### ***Western blotting***

Embryos were manually deyolked at the desired stage and snap frozen in liquid nitrogen. For all proteins, equal numbers of embryos were analyzed for each developmental stage (H4 and H2A [ $n = 10$ ], all other proteins [ $n = 5$ ]). Samples were boiled with SDS loading buffer at 98°C, run on 4-12% polyacrylamide NuPAGE Bis-Tris gels (NP0321BOX; ThermoFisher Scientific) and blotted onto a nitrocellulose membrane (10600002; GE Life Sciences, Chicago, IL). Primary antibodies were incubated at RT for 1 hour or overnight at 4°C and secondary antibodies were incubated at RT for 45 min. Primary and secondary antibodies used are listed in Table 3 and 4 respectively. Membranes were analyzed on an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE) or via chemiluminescent detection (GE Life Sciences) and X-ray film (GE Life Sciences). Tubulin was examined visually on all blots as a loading control.

### ***Quantitative mass spectrometry***

We selected five proteotypic peptides (Worboys et al., 2014) for each of the four histones: H3, H4, H2A and H2B. The peptides do not discriminate between known histone variants for H3 and H2A. A chimeric gene encoding these peptides (Beynon et al.,

2005) in addition to reference peptides from BSA and Glycogen Phosphorylase B (PhosB) (five each), and flanked by Strep- and His-tags, was chemically synthesized (Gene Art, ThermoFisher Scientific). This gene was expressed in a Lys, Arg dual-auxotroph *E. coli* strain (BL21DE3pRARE) that was grown in media complemented with  $^{13}\text{C}^{15}\text{N}$ -Arg and  $^{13}\text{C}$ -Lys (Silantes, Munich, Germany). In a separate LC-MS/MS experiment we established that the full-length chimeric protein was correctly expressed and the rate of incorporation of isotopically labeled amino acids was ca. 99%. The gel band corresponding to the chimeric protein was co-digested with the gel slab containing the histones from the samples of interest (Shevchenko et al., 2006) and with the band containing the exactly known amount of the reference protein (BSA). The recovered tryptic peptides were analysed by nanoLC-MS/MS on a LTQ Orbitrap Velos coupled with Dionex Ultimate 3000 nano-HPLC system (ThermoFisher Scientific). Three biological replicates were analyzed for each sample, with two technical replicates for each sample. The peptides were fractionated using C18 reversed phase column (Acclaim PepMap 100) over a linear gradient from 0-55% solvent B in solvent A, delivered in 120 min (Solvent A 0.1% FA, Solvent B 60% ACN+0.1% FA). The identification of peptides was performed using Mascot v2.2.04 (Matrix Science, London, United Kingdom) against a custom made database composed of sequences from all histones, BSA, PhosB, affinity tag and the sequences of common contaminants such as human keratins and porcine trypsin. The raw abundances of extracted ion chromatograms (XIC) peaks of peptide precursors were reported by Progenesis LC-MS v4.1 software (Nonlinear Dynamics, Newcastle, United Kingdom). First the chimeric protein was quantified by comparing the abundances of BSA peptides comprised in its sequence with the corresponding peptides

obtained by co-digestion of a known amount of BSA protein standard. In turn, the molar content of target zebrafish histones was inferred from the content of the chimera protein and the ratio of relative abundances of XIC peaks of precursor ions of matching pairs of labeled (originating from chimera) and unlabeled (originating from histones) peptides. Note that all peptides were recovered from the same in-gel digest and quantified at the same LC-MS/MS run.

### ***Histone calculations***

Absolute histone amounts were measured using mass spectrometry. The number of histones bound to a diploid zebrafish genome was calculated as 31,324,994 per genome for each histone. To arrive at this calculation (Figure 4-source data 1), we have previously shown that the average distance between the centers of neighboring nucleosomes in the zebrafish embryo around genome activation is 187 base pairs (Zhang et al., 2014). The size of a zebrafish genome is 1.46 Gb (GRCz10). This was multiplied by two to reach the diploid genome size which was then divided by the nucleosome repeat length to arrive at the number of nucleosomes per genome. As each histone is represented twice in a nucleosome, this number was multiplied by two to arrive at  $3.13 \times 10^7$  copies of each histone that are required to wrap one zebrafish genome into chromatin (see Figure 4-source data 1). To arrive at numbers of histones in ‘genomes worth of histones’, the actual number of histones was divided by the amount of histones required to wrap one diploid genome. For the excess of histones per cell calculation (Figure 4D), the level of H2B (Figure 4-source data 1) and the cell numbers in Figure 1-source data 1 were used. Because we have shown that all four core histones contribute to

the repressor effect, we used the level of H2B for these calculations, as H2B is the lowest abundant histone and therefore may be limiting for the formation of nucleosomes. We subtracted the number of histones that are assumed to be bound to DNA, which amounts to 1 to 2 genomes worth of histones assuming replication (we used the average). The total concentration of non-DNA bound histones was calculated by dividing the total amount of non-DNA bound histones by the volume of the animal cap (Figure 4-figure supplement 1A).

### ***Histone cocktail***

Recombinant histones were of human origin and produced in *E. Coli* (NEB, Ipswich, MA; 1 mg/ml: H3.1 M2503S, H4 M2504S, H2A M2502S, H2B M2505S). We used human histones because histones are highly conserved between species and these are readily available. To remove DTT, H3.1 was dialyzed in histone buffer (300 mM NaCl, 1 mM EDTA, 20 mM NaPO<sub>4</sub>, pH 7.0 at 25°C) using a Slide-A-Lyzer MINI dialysis device, 7K MWCO (ThermoFisher Scientific) at RT for 30 min or at 4°C overnight. Stoichiometric amounts of all four core histones were combined, spun for 5 min at 6,600 rcf on a bench top centrifuge, supernatant was removed, and recovery of histones was measured via quantitative Western blot analysis and calculated using a standard. On average 5756 genomes worth of histone were injected with an error of  $\pm 388$  (n=3).

### ***NanoString analysis***

This method involves assigning a unique color-coded barcode to transcripts of interest for single molecule imaging and counting. The number of times the unique barcode is

detected, is used as a readout of the expression level or number of ‘counts’ for the gene of interest. We developed a custom-made probe set of zygotically expressed genes as well as control genes (Figure 2- figure 2 source data 1). Probe-sets were hybridized to 100 ng of mRNA extracted from a batch of 25 embryos using the RNeasy Mini Kit and processed following the manufacturer’s recommendations (NanoString Technologies, Seattle, WA) (Kulkarni, 2011). More information about the analysis can be found in the legend of Figure 2-figure supplement 2.

### ***Chromatin fractionation***

At the desired stage, 65-100 embryos were manually deyolked and snap frozen in a cell lysis buffer (CLB: 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.34 M sucrose, 10% glycerol, 0.1% NP-40, 1x protease inhibitor (Roche, Basel, Switzerland)) (Méndez and Stillman, 2000). Thawed embryos were shaken at 4°C for 5 min, then placed on ice and flicked intermittently for 5 min. Samples were spun in a bench top centrifuge at 1,700 rcf for 5 min. Supernatant was removed and the pellet was washed with CLB. After another spin, the pellet was washed with a nuclear lysis buffer (3 mM EDTA, 0.2 mM EGTA). The sample was spun down and resuspended with high-salt solubilization buffer (50 mM Tris-HCL pH 8.0, 2.5 M NaCl, 0.05% NP-40, 1x protease inhibitor) (Shechter et al., 2008). The sample was vortexed for 2 min and placed on a rotator at RT for 10 min. The complete sample was then used in Western blot analysis.

### ***Co-immunoprecipitation***

Per IP, 500 staged embryos were deyolked as previously described (Link et al., 2006).

Cells were immediately resuspended in cell lysis buffer (10 mM Tris-HCl at pH 7.5, 10 mM NaCl, 0.5% NP-40, 1x protease inhibitor (Roche)), and lysed for 15 min on ice. Nuclei were pelleted by centrifugation and the supernatant was collected and rotated overnight at 4°C with 25 mL of protein G magnetic Dynabeads (Invitrogen, Carlsbad, CA) that had been pre-bound to an excess amount of antibody. Bound complexes were washed six times with RIPA buffer (50 mM HEPES at pH 7.6, 1 mM EDTA, 0.7% DOC, 1% Igepal, 0.5 M LiCl, 1x protease inhibitor) followed by 10 min of boiling in SDS loading buffer. Beads from the sample were subsequently removed by centrifugation and Western blotting was used for further analysis.

### ***Cy5 labeling***

Histone H4 was incubated with Cyanine5 NHS ester (10:1 molar ratio) (Lumiprobe, Hannover, Germany) rotating overnight at 4°C. The next day, the solution was dialyzed in histone buffer for 30 min at RT. ~1 ng was injected into embryos of the Tg(h2afz:h2afz-GFP) transgenic fish line (Pauls et al., 2001) and embryos were imaged live on an upright LSM 510 META microscope equipped with a Zeiss W Plan-Apochromat 40x 1.0 dipping objective. GFP was excited at 488 nm, detected with a PMT using BP527.5/545 and a pinhole size of 72  $\mu\text{m}$ . Cy5 was excited at 633 nm, detected with the META detector using BP649-756 and a pinhole size of 96  $\mu\text{m}$ . Images are 512\*512 pixels, pixel size is 0.22  $\mu\text{m}$  and were acquired with 8-bit mode.

### ***Quantification of nuclear concentration of non-DNA bound histones***

We determined the concentration of non-DNA bound histones in the nucleus as follows. First, we obtained volumetric data from live embryos, in which H4-sfGFP fusion protein

was translated from injected mRNA to label animal cap and cell nuclei, at low and high intensity levels, respectively (see ‘Live embryo tracking of nuclei and animal cap volumes’ and ‘Automated image analysis’ below). Imaging live embryos prevented volume alterations due to fixation, permeabilization, and wash steps in immunofluorescence. Next, we determined relative histone distributions in cytoplasm and nucleus by immunofluorescence detection of endogenous histone H4, thus avoiding potential offsets or sub-cellular redistribution of the endogenous histone pool due to the addition of labeled fusion protein (see ‘Immunofluorescence’ and ‘Automated image analysis’ below). Then, we combined volumetric and nuclear-over-cytoplasmic intensity ratio data to allocate the total amount of histone H4 per embryo, as measured by mass spectrometry (Figure 4-source data 1), to the cytoplasmic and the nuclear sub-compartment (see ‘Calculation of non-DNA bound nuclear histone concentration’ below). Lastly, aiming to calculate the concentration of only non-DNA bound histones, the histones bound on chromatin in a given nucleus were subtracted from the total nuclear concentration of histones.

### ***Live embryo tracking of nuclei and animal cap volumes***

To monitor the volumes of the animal cap and individual nuclei as well as nuclear import dynamics, histone H4 and PCNA were imaged in whole live embryos at a time resolution of 2 min or faster (see movie 1). H4 was introduced as a fusion with sfGFP by mRNA injection. PCNA was monitored using offspring of transgenic fish with PCNA-RFP (Tg(bactin:RFP-pcna) (Strzyz et al., 2015)).

Embryos were mounted in glass capillaries with 1% low melting agarose (Invitrogen) dissolved in 0.3x Danieau's solution and imaged with a Zeiss Z.1 lightsheet microscope using a 10x water dipping objective (NA 0.5) for acquisition, a lightsheet thickness below 5  $\mu\text{m}$ , and dual side illumination (Icha et al., 2016). The microscopy chamber was filled with 0.3x Danieau's and kept at 28.5°C. Optical sectioning was 1 or 1.5  $\mu\text{m}$ , time resolution was 2 min or faster for the acquisition of a whole 3D stack.

### ***Immunofluorescence***

A time series of wild-type TLAB embryos covering 64-cell to sphere stages was collected, immunostained following a protocol optimized for full transparency and penetration of antibody, and imaged using a Zeiss Z.1 lightsheet microscope. Wild-type TLAB embryos were transferred at a given stage by transfer from 0.3x Danieau's into 2% formaldehyde in 0.3x Danieau's with 0.2% Tween-20 and left to fix overnight at 4°C. On the next day, embryos were washed three times for 10 min in PBST (Dulbecco's PBS with 0.1% Tween-20), then further permeabilized by washing twice in double distilled water followed by 5 min waiting at room temperature, and then blocked with 4% BSA in PBST with 1% DMSO for at least 30 min. Primary antibodies against histone H4 and RNA polymerase II were diluted in 2% BSA in PBST with 1% DMSO and applied for incubation at 4°C for at least 48 hours. Embryos were washed three times for 10 min in PBST. Secondary antibodies were diluted in 2% BSA in PBST with 1% DMSO and applied overnight or longer at 4°C. Embryos were then washed three times for at least 10 min in PBST and stored at 4°C until imaging. Mounting for imaging was done in glass capillaries using 2% low melting agarose dissolved in Dulbecco's PBS. 3D stacks were

acquired using a 20x water dipping objective (NA 1.0) for acquisition, a lightsheet thickness below 5  $\mu\text{m}$ , and dual side illumination. The microscopy chamber was filled with Dulbecco's PBS Optical sectioning was 1  $\mu\text{m}$  or less.

### *Automated image analysis*

Microscopy data were analyzed with a custom MatLab code using the Open Microscopy Environment bioformats plugin for stack reading. Nuclei were segmented using iterative thresholding for individual nuclei to compensate for differing intensities across the sample. 3D segments representing nuclei were dilated in two steps, giving a once- and a twice-extended shell around any given nucleus (Stasevich et al., 2014). The once-extended shell was removed from the twice-extended shell, along with any other nuclei that happened to be covered by the twice-extended shell. The resulting 3D segment thus covered cytoplasm in the vicinity of a given nucleus. The nucleus and the cytoplasm 3D segments were then used as masks to extract the mean intensity of a given cell's nucleus and cytoplasm. The animal cap was segmented in 3D based a single, global threshold determined from maximum intensity z-projections using Otsu's method. (For code, see Hilbert L. 2016 GitHub. [https://github.com/lhilbert/NCRatio\\_Analysis](https://github.com/lhilbert/NCRatio_Analysis). a7a5849).

For live imaging data, individual nuclei were tracked across consecutive time frames based on minimal centroid distances. The volume fraction of the animal cap taken up by nuclei was calculated from the sum of volumes of all nuclei detected in a given stage, at their individual times of maximal extension in the respective cell cycle. (For code, see

Hilbert L. 2016 GitHub. [https://github.com/lhilbert/NucCyto\\_Ratio\\_TimeLapse](https://github.com/lhilbert/NucCyto_Ratio_TimeLapse).  
55ed0fc).

For immunofluorescence data, nuclei were segmented based on the Pol II signal, which exhibited strong nuclear localization during interphase for all stages. Nuclear and cytoplasmic intensities for both Pol II and H4 were then extracted based on the Pol II segmentation as described above. To remove nuclei that were not in interphase or suffered signal degradation due to excessive spherical aberration or out-of-focus light, only nuclei with a nuclear-over-cytoplasmic intensity ration of greater than 2 were included in the analysis. Intensity ratios were strongly affected by background staining, so that H4 intensity values were corrected by subtraction of background levels before calculating ratios. Background levels were obtained from control embryos incubated with secondary, but not primary antibodies, which were imaged in the same session and with the same settings as the fully stained samples.

### ***Calculation of non-DNA bound nuclear histone concentration***

To obtain nuclear histone concentration values, one considers that the total number of histones must correspond to the contributions from all cells' cytoplasm and nuclei,

$$H_{total} = [H_{nuclear}] \times V_{nucleus}^{sum} + [H_{cytoplasm}] \times V_{cytoplasm}^{sum},$$

where  $H_{total}$ ,  $H_{nuclear}$ ,  $H_{cytoplasm}$  are the total, the nuclear, and the cytoplasmic concentration of endogenous histone H4, respectively.  $V_{nucleus}^{sum}$  and  $V_{cytoplasm}^{sum}$  are the summed volumes of all cells' nuclei and cytoplasm, respectively. Dividing both sides by the total animal cap volume,  $V_{total}$ , one finds

$$\frac{H_{total}}{V_{total}} = [H_{nuclear}] \times v + [H_{cytoplasm}] \times (1 - v),$$

where  $v = V_{nucleus}^{sum}/V_{total}$  is the fraction of the total animal cap volume taken up by nuclei (also corresponds to the average fraction of cell volume occupied by the cell nucleus). Considering the N/C intensity ratio,  $R$ , to represent the concentration ratio,  $R \approx [H_{nuclear}]/[H_{cytoplasm}]$ , one can solve for  $[H_{nuclear}]$ ,

$$[H_{nuclear}] = \frac{H_{total}}{V_{total}} \times \frac{R}{1 + v(R - 1)}.$$

Realizing that this measured nuclear concentration results from non-DNA bound histones as much as chromatin bound histones, one needs to subtract the concentration of chromatin bound histones to arrive at the non-DNA bound histone H4 concentration,

$$[H_{free}] = [H_{nucleus}] - [H_{bound}] = [H_{nucleus}] - \frac{g}{V_{nucleus}^{single}}.$$

$g$  quantifies the number of complete, histone wrapped genomes (in units of genomes worth) being present in the volume of an individual nucleus,  $V_{nucleus}^{single}$ . Dropping the *single* superscript for ease of notation, the final expression is

$$[H_{free}] = \frac{H_{total}}{V_{total}} \times \frac{R}{1 + v(R - 1)} - \frac{g}{V_{nucleus}}.$$

We measured all variables except  $g$  on the right hand side using mass spectrometry ( $[H_{total}]$ ), lightsheet imaging of whole live embryos injected with mRNA for H4-sfGFP ( $V_{total}, v, V_{nucleus}$ , see above), or immunofluorescence of endogenous histone H4 ( $R$ ) (see Figure S4B).  $g$  was assigned a value of 1.5 genomes worth, to fall between 1 (before

replication of the genome) and 2 (complete replication of the genome), under the assumption of full occupation of the DNA by histones.

### ***Chromatin immunoprecipitation***

Per IP, ~550 staged embryos were fixed at RT for 15 min in 1.85% formaldehyde. The fixative was quenched with 125 mM glycine and rotation at RT for 5 min. Embryos were then rinsed 3x in ice cold PBS (Accugene, Willowbrook, IL), resuspended in cell lysis buffer (same as co-IP) and lysed for 15 min on ice. Nuclei were pelleted by centrifugation, resuspended in nuclear lysis buffer (50 mM Tris-HCl at pH 7.5, 10 mM EDTA, 1% SDS, 1x protease inhibitor) and lysed for 10 min on ice. Two volumes of IP dilution buffer (16.7 mM Tris-HCl at pH 7.5, 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS, 1x protease inhibitor) was added and the sample was sonicated to produce DNA fragments of between 200-300 bp (for Pou5f3-2xHA ChIP) or 400-500 bp (for tTA-VP16-2xHA ChIP) as determined using a bioanalyzer. 0.8% Triton X was added to the chromatin, which was then centrifuged to remove residual cellular debris. A sample was saved for input and the rest was divided over 25 mL of protein G magnetic Dynabeads that had been pre-bound to an excess amount of either HA antibody or IgG control antibody (Table 3). These were rotated overnight at 4°C. Bound complexes were washed six times with RIPA buffer followed by TBS. Elution buffer (50 mM NaHCO<sub>3</sub>, 1% SDS) was added to the beads, which were then vortexed and incubated for 15 min at RT on a rotator. Elutant was collected after centrifugation at 13,200 rcf, and beads were subjected to a repetition of the elution step. The same volume of elution buffer was added to the input sample, and 300mM NaCl was added to all samples to reverse crosslink at 65°C

overnight. Three volumes of 100% ethanol was added and samples were incubated for 1h at -80°C. Samples were spun at 13,200 rcf at 4°C for 10 min followed by supernatant removal and air drying. 100 µL water was added and samples were shaken at RT for 5 hours. A PCR purification kit (Qiagen) was used before qPCR analysis.

### ***Sample-size determination***

A minimum of 3 biological replicates were used for each experiment, with most experiments having 4 or more biological replicates (see figure legends for sample size).

## ACKNOWLEDGEMENTS

This work was supported by MPI-CBG core funding, a Human Frontier Science Program Career Development Award (CDA00060/2012) to NLV, a fellowship of the Dresden International Graduate School for Biomedicine and Bioengineering (DIGS-BB) granted by the German Research Foundation (DFG) to SRJ and MK, and an ELBE Postdoctoral Fellowship granted by the Center for Systems Biology Dresden to LH. We thank members of the Vastenhouw laboratory, F. Buchholz, D. Drechsel and K. Steinberg-Bains for help and advice, J. Bruges, M. Krause, Y.T. Lin, I. K. Patten, P. Tomancak, A. Tóth, and J. Rink for discussions and critical reading of the manuscript, the Norden lab for kindly providing the Tg(bactin:RFP-pcna) fish and the following MPI-CBG Services and Facilities for their support: the Biomedical Services (Fish unit), the Light Microscopy Facility, and Scientific Computing.

## REFERENCES

- Aanes, H., Winata, C.L., Lin, C.H., Chen, J.P., Srinivasan, K.G., Lee, S.G.P., Lim, A.Y.M., Hajan, H.S., Collas, P., Bourque, G., et al. (2011). Zebrafish mRNA sequencing deciphers novelties in transcriptome dynamics during maternal to zygotic transition. *Genome Research* *21*, 1328–1338.
- Adamson, E.D., and Woodland, H.R. (1974). Histone synthesis in early amphibian development: histone and DNA syntheses are not co-ordinated. *Journal of Molecular Biology* *88*, 263–285.
- Almouzni, G., and Wolffe, A.P. (1993). Replication-coupled chromatin assembly is required for the repression of basal transcription in vivo. *Genes & Development* *7*, 2033–2047.
- Almouzni, G., and Wolffe, A.P. (1995). Constraints on transcriptional activator function contribute to transcriptional quiescence during early *Xenopus* embryogenesis. *Embo J* *14*, 1752–1765.
- Almouzni, G., Méchali, M., and Wolffe, A.P. (1990). Competition between transcription complex assembly and chromatin assembly on replicating DNA. *Embo J* *9*, 573–582.
- Amodeo, A.A., Jukam, D., Straight, A.F., and Skotheim, J.M. (2015). Histone titration against the genome sets the DNA-to-cytoplasm threshold for the *Xenopus* midblastula transition. *Proceedings of the National Academy of Sciences* *112*, E1086–E1095.
- Belting, H.-G., Wendik, B., Lunde, K., Leichsenring, M., Mössner, R., Driever, W., and Onichtchouk, D. (2011). Pou5f1 contributes to dorsoventral patterning by positive regulation of *vox* and modulation of *fgf8a* expression. *Developmental Biology* *356*, 323–336.
- Beynon, R.J., Doherty, M.K., Pratt, J.M., and Gaskell, S.J. (2005). Multiplexed absolute quantification in proteomics using artificial QCAT proteins of concatenated signature peptides. *Nat Meth* *2*, 587–589.
- Blythe, S.A., and Wieschaus, E.F. (2015a). Coordinating Cell Cycle Remodeling with Transcriptional Activation at the *Drosophila* MBT. *Curr. Top. Dev. Biol.* *113*, 113–148.
- Blythe, S.A., and Wieschaus, E.F. (2015b). Zygotic genome activation triggers the DNA replication checkpoint at the midblastula transition. *Cell* *160*, 1169–1181.
- Bottazzi, B., Doni, A., Garlanda, C., and Mantovani, A. (2010). An integrated view of humoral innate immunity: pentraxins as a paradigm. *Annu. Rev. Immunol.* *28*, 157–183.
- Burgess, S., Reim, G., Chen, W., Hopkins, N., and Brand, M. (2002). The zebrafish *spiel-ohne-grenzen* (*spg*) gene encodes the POU domain protein Pou2 related to mammalian Oct4 and is essential for formation of the midbrain and hindbrain, and for pre-gastrula morphogenesis. *Development* *129*, 905–916.

Cheloufi, S., Elling, U., Hopfgartner, B., Jung, Y.L., Murn, J., Ninova, M., Hubmann, M., Badeaux, A.I., Euong Ang, C., Tenen, D., et al. (2015). The histone chaperone CAF-1 safeguards somatic cell identity. *Nature* *528*, 218–224.

Chen, J., Zhang, Z., Li, L., Chen, B.-C., Revyakin, A., Hajj, B., Legant, W., Dahan, M., Lionnet, T., Betzig, E., et al. (2014). Single-molecule dynamics of enhanceosome assembly in embryonic stem cells. *Cell* *156*, 1274–1285.

Collart, C., Allen, G.E., Bradshaw, C.R., Smith, J.C., and Zegerman, P. (2013). Titration of Four Replication Factors Is Essential for the *Xenopus laevis* Midblastula Transition. *Science* *341*, 893–896.

Collart, C., Owens, N.D.L., Bhaw-Rosun, L., Cooper, B., De Domenico, E., Patrushev, I., Sesay, A.K., Smith, J.N., Smith, J.C., and Gilchrist, M.J. (2014). High-resolution analysis of gene activity during the *Xenopus* mid-blastula transition. *Development* *141*, 1927–1939.

Daigo, K., Nakakido, M., Ohashi, R., Fukuda, R., Matsubara, K., Minami, T., Yamaguchi, N., Inoue, K., Jiang, S., Naito, M., et al. (2014). Protective effect of the long pentraxin PTX3 against histone-mediated endothelial cell cytotoxicity in sepsis. *Science Signaling* *7*, ra88–ra88.

De Renzis, S., Elemento, O., Tavazoie, S., and Wieschaus, E.F. (2007). Unmasking Activation of the Zygotic Genome Using Chromosomal Deletions in the *Drosophila* Embryo. *Plos Biol* *5*, e117.

Dekens, M.P.S., Pelegri, F.J., Maischein, H.M, Nüsslein-Volhard, C. (2003). The maternal-effect gene futile cycle is essential for pronuclear congression and mitotic spindle assembly in the zebrafish zygote. *Development* *130*, 3907–3916.

Edgar, B.A., and Schubiger, G. (1986). Parameters Controlling Transcriptional Activation During Early *Drosophila* Development. *Cell* *44*, 871–877.

Fennessy, R.T., and Owen-Hughes, T. (2016). Establishment of a promoter-based chromatin architecture on recently replicated DNA can accommodate variable inter-nucleosome spacing. *Nucleic Acids Research* *44*, 7189–7203.

Feser, J., Truong, D., Das, C., Carson, J.J., Kieft, J., Harkness, T., and Tyler, J.K. (2010). Elevated histone expression promotes life span extension. *Molecular Cell* *39*, 724–735.

Foo, S.M., Sun, Y., Lim, B., Ziukaite, R., O'Brien, K., Nien, C.-Y., Kirov, N., Shvartsman, S.Y., and Rushlow, C.A. (2014). Zelda potentiates morphogen activity by increasing chromatin accessibility. *Curr Biol* *24*, 1341–1346.

Harrison, M.M., and Eisen, M.B. (2015). Transcriptional Activation of the Zygotic Genome in *Drosophila*. *Curr. Top. Dev. Biol.* *113*, 85–112.

Harrison, M.M., Botchan, M.R., and Cline, T.W. (2010). Grainyhead and Zelda compete

for binding to the promoters of the earliest-expressed *Drosophila* genes. *Developmental Biology* 345, 248–255.

Harrison, M.M., Li, X.-Y., Kaplan, T., Botchan, M.R., and Eisen, M.B. (2011). Zelda Binding in the Early *Drosophila melanogaster* Embryo Marks Regions Subsequently Activated at the Maternal-to-Zygotic Transition. *PLoS Genet* 7, e1002266.

Harvey, S.A., Sealy, I., Kettleborough, R., Fenyes, F., White, R., Stemple, D., and Smith, J.C. (2013). Identification of the zebrafish maternal and paternal transcriptomes. *Development* 140, 2703–2710.

Hayes, J.J., and Wolffe, A.P. (1992). Histones H2A/H2B inhibit the interaction of transcription factor IIIA with the *Xenopus borealis* somatic 5S RNA gene in a nucleosome. *Proc Natl Acad Sci USA* 89, 1229–1233.

Heyn, P., Kircher, M., Dahl, A., Kelso, J., Tomancak, P., Kalinka, A.T., and Neugebauer, K.M. (2014). The earliest transcribed zygotic genes are short, newly evolved, and different across species. *CellReports* 6, 285–292.

Hu, Z., Chen, K., Xia, Z., Chavez, M., Pal, S., Seol, J.-H., Chen, C.-C., Li, W., and Tyler, J.K. (2014). Nucleosome loss leads to global transcriptional up-regulation and genomic instability during yeast aging. *Genes & Development* 28, 396–408.

Ishiuchi, T., Enriquez-Gasca, R., Mizutani, E., Bošković, A., Ziegler-Birling, C., Rodriguez-Terrones, D., Wakayama, T., Vaquerizas, J.M., and Torres-Padilla, M.-E. (2015). Early embryonic-like cells are induced by downregulating replication-dependent chromatin assembly. *Nat Struct Mol Biol* 22, 662–671.

Jevtić, P., and Levy, D.L. (2015). Nuclear size scaling during *Xenopus* early development contributes to midblastula transition timing. *Curr Biol* 25, 45–52.

Kane, D.A., and Kimmel, C.B. (1993). The zebrafish midblastula transition. *Development* 119, 447–456.

Kane, D.A., Hammerschmidt, M., Mullins, M.C., Maischein, H.M., Brand, M., van Eeden, F.J., Furutani-Seiki, M., Granato, M., Haffter, P., Heisenberg, C.P., et al. (1996). The zebrafish epiboly mutants. *Development* 123, 47–55.

Karnavas, T., Pintonello, L., Agresti, A., and Bianchi, M.E. (2014). Histone content increases in differentiating embryonic stem cells. *Front Physiol* 5, 330.

Keller, P.J., Schmidt, A.D., Wittbrodt, J., and Stelzer, E.H.K. (2008). Reconstruction of zebrafish early embryonic development by scanned light sheet microscopy. *Science* 322, 1065–1069.

Kim, S., and Elbaum, M. (2013a). A simple kinetic model with explicit predictions for nuclear transport. *Biophysical Journal* 105, 565–569.

- Kim, S., and Elbaum, M. (2013b). Enzymatically driven transport: a kinetic theory for nuclear export. *Biophysical Journal* *105*, 1997–2005.
- Kimelman, D., Kirschner, M., and Scherson, T. (1987). The events of the midblastula transition in *Xenopus* are regulated by changes in the cell cycle. *Cell* *48*, 399–407.
- Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B., and Schilling, T.F. (1995). Stages of embryonic development of the zebrafish. *Dev Dyn* *203*, 253–310.
- Kopito, R.B., and Elbaum, M. (2007). Reversibility in nucleocytoplasmic transport. *Proc Natl Acad Sci USA* *104*, 12743–12748.
- Kopito, R.B., and Elbaum, M. (2009). Nucleocytoplasmic transport: a thermodynamic mechanism. *Hfsp J* *3*, 130–141.
- Kulkarni, M.M. (2011). Digital multiplexed gene expression analysis using the NanoString nCounter system. *Curr Protoc Mol Biol Chapter 25*, Unit25B.10–25B.10.17.
- Langheinrich, U., Hennen, E., Stott, G., and Vacun, G. (2002). Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. *Curr Biol* *12*, 2023–2028.
- Lee, M.T., Bonneau, A.R., and Giraldez, A.J. (2014). Zygotic genome activation during the maternal-to-zygotic transition. *Annu. Rev. Cell. Dev. Biol.* *30*, 581–613.
- Lee, M.T., Bonneau, A.R., Takacs, C.M., Bazzini, A.A., DiVito, K.R., Fleming, E.S., and Giraldez, A.J. (2013). Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition. *Nature* *503*, 360–364.
- Leichsenring, M., Maes, J., Mossner, R., Driever, W., and Onichtchouk, D. (2013). Pou5f1 Transcription Factor Controls Zygotic Gene Activation In Vertebrates. *Science* *341*, 1005–1009.
- Li, Z., Thiel, K., Thul, P.J., Beller, M., Kühnlein, R.P., and Welte, M.A. (2012). Lipid Droplets Control the Maternal Histone Supply of *Drosophila* Embryos. *Curr Biol* *22*, 2104–2113.
- Liang, H.-L., Nien, C.-Y., Liu, H.-Y., Metzstein, M.M., Kirov, N., and Rushlow, C. (2008). The zinc-finger protein Zelda is a key activator of the early zygotic genome in *Drosophila*. *Nature* *456*, 400–403.
- Lindeman, L.C., Andersen, I.S., Reiner, A.H., Li, N., Aanes, H., Østrup, O., Winata, C., Mathavan, S., Müller, F., Aleström, P., et al. (2011). Prepatterning of Developmental Gene Expression by Modified Histones before Zygotic Genome Activation. *Dev Cell* *1–12*.
- Link, V., Shevchenko, A., and Heisenberg, C.-P. (2006). Proteomics of early zebrafish embryos. *BMC Dev Biol* *6*, 1.

- Lott, S.E., Villalta, J.E., Schroth, G.P., Luo, S., Tonkin, L.A., and Eisen, M.B. (2011). Noncanonical Compensation of Zygotic X Transcription in Early *Drosophila melanogaster* Development Revealed through Single-Embryo RNA-Seq. *Plos Biol* *9*, e1000590–13.
- Lu, X., Li, J.M., Elemento, O., Tavazoie, S., and Wieschaus, E.F. (2009). Coupling of zygotic transcription to mitotic control at the *Drosophila* mid-blastula transition. *Development* *136*, 2101–2110.
- Marzluff, W.F., and Duronio, R.J. (2002). Histone mRNA expression: multiple levels of cell cycle regulation and important developmental consequences. *Curr Opin Cell Biol* *14*, 692–699.
- Méndez, J., and Stillman, B. (2000). Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. *Molecular and Cellular Biology* *20*, 8602–8612.
- Miller, J.A., and Widom, J. (2003). Collaborative competition mechanism for gene activation in vivo. *Molecular and Cellular Biology* *23*, 1623–1632.
- Mirny, L.A. (2010). Nucleosome-mediated cooperativity between transcription factors. *Proceedings of the National Academy of Sciences* *107*, 22534–22539.
- Newport, J., and Kirschner, M. (1982a). A major developmental transition in early *Xenopus* embryos: II. Control of the onset of transcription. *Cell* *30*, 687–696.
- Newport, J., and Kirschner, M. (1982b). A major developmental transition in early *Xenopus* embryos: I. characterization and timing of cellular changes at the midblastula stage. *Cell* *30*, 675–686.
- Nien, C.-Y., Liang, H.-L., Butcher, S., Sun, Y., Fu, S., Gocha, T., Kirov, N., Manak, J.R., and Rushlow, C. (2011). Temporal coordination of gene networks by Zelda in the early *Drosophila* embryo. *PLoS Genet* *7*, e1002339.
- Nurse, P. (1983). Coordinating histone transcription and DNA replication. *Nature* *302*, 378.
- O'Sullivan, R.J., Kubicek, S., Schreiber, S.L., and Karlseder, J. (2010). Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. *Nat Struct Mol Biol* *17*, 1218–1225.
- Okuda, Y., Ogura, E., Kondoh, H., and Kamachi, Y. (2010). B1 SOX coordinate cell specification with patterning and morphogenesis in the early zebrafish embryo. *PLoS Genet* *6*, e1000936.
- Olson, E.J., Hartsough, L.A., Landry, B.P., Shroff, R., and Tabor, J.J. (2014). Characterizing bacterial gene circuit dynamics with optically programmed gene

expression signals. *Nat Meth* *11*, 449–455.

Onichtchouk, D., Geier, F., Polok, B., Messerschmidt, D.M., Mössner, R., Wendik, B., Song, S., Taylor, V., Timmer, J., and Driever, W. (2010). Zebrafish Pou5f1-dependent transcriptional networks in temporal control of early development. *Molecular Systems Biology* *6*, 354.

Osley, M.A. (1991). The regulation of histone synthesis in the cell cycle. *Annu. Rev. Biochem.* *60*, 827–861.

Owens, N.D.L., Blitz, I.L., Lane, M.A., Patrushev, I., Overton, J.D., Gilchrist, M.J., Cho, K.W.Y., and Khokha, M.K. (2016). Measuring Absolute RNA Copy Numbers at High Temporal Resolution Reveals Transcriptome Kinetics in Development. *CellReports* *14*, 632–647.

Pauli, A., Valen, E., Lin, M.F., Garber, M., Vastenhouw, N.L., Levin, J.Z., Fan, L., Sandelin, A., Rinn, J.L., Regev, A., et al. (2012). Systematic identification of long noncoding RNAs expressed during zebrafish embryogenesis. *Genome Research* *22*, 577–591.

Pauls, S., Geldmacher-Voss, B., and Campos-Ortega, J.A. (2001). A zebrafish histone variant H2A.F/Z and a transgenic H2A.F/Z:GFP fusion protein for in vivo studies of embryonic development. *Dev Genes Evol* *211*, 603–610.

Pei, W., Noushmehr, H., Costa, J., Ouspenskaia, M.V., Elkahloun, A.G., and Feldman, B. (2007). An early requirement for maternal FoxH1 during zebrafish gastrulation. *Developmental Biology* *310*, 10–22.

Pérez-Montero, S., Carbonell, A., Morán, T., Vaquero, A., and Azorín, F. (2013). The Embryonic Linker Histone H1 Variant of *Drosophila*, dBigH1, Regulates Zygotic Genome Activation. *Dev Cell* *26*, 578–590.

Prioleau, M.N., Buckle, R.S., and Méchali, M. (1995). Programming of a repressed but committed chromatin structure during early development. *Embo J* *14*, 5073–5084.

Prioleau, M.N., Huet, J., Sentenac, A., and Méchali, M. (1994). Competition between chromatin and transcription complex assembly regulates gene expression during early development. *Cell* *77*, 439–449.

Ramachandran, S., and Henikoff, S. (2016). Transcriptional Regulators Compete with Nucleosomes Post-replication. *Cell* *165*, 580–592.

Raveh-Sadka, T., Levo, M., Shabi, U., Shany, B., Keren, L., Lotan-Pompan, M., Zeevi, D., Sharon, E., Weinberger, A., and Segal, E. (2012). Manipulating nucleosome disfavoring sequences allows fine-tune regulation of gene expression in yeast. *Nat Genet* *44*, 743–750.

Sandler, J.E., and Stathopoulos, A. (2016). Quantitative Single-Embryo Profile of

Drosophila Genome Activation and the Dorsal-Ventral Patterning Network. *Genetics* 202, 1575–1584.

Schild-Poulter, C., Sassone-Corsi, P., Granger-Schnarr, M., and Schnarr, M. (1996). Nucleosome assembly on the human *c-fos* promoter interferes with transcription factor binding. *Nucleic Acids Research* 24, 4751–4758.

Shechter, D., Nicklay, J.J., Chitta, R.K., Shabanowitz, J., Hunt, D.F., and Allis, C.D. (2008). Analysis of Histones in *Xenopus laevis*: I. A distinct index of enriched variants and modifications exists in each cell type and is remodeled during developmental transitions. *Journal of Biological Chemistry* 284, 1064–1074.

Shevchenko, A., Tomas, H., Havlis, J., Olsen, J.V., and Mann, M. (2006). In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc* 1, 2856–2860.

Skirkanich, J., Luxardi, G., Yang, J., Kodjabachian, L., and Klein, P.S. (2011). An essential role for transcription before the MBT in *Xenopus laevis*. *Developmental Biology* 1–14.

Soufi, A., Donahue, G., and Zaret, K.S. (2012). Facilitators and Impediments of the Pluripotency Reprogramming Factors' Initial Engagement with the Genome. *Cell* 151, 994–1004.

Stasevich, T.J., Sato, Y., Nozaki, N., and Kimura, H. (2014). Quantifying histone and RNA polymerase II post-translational modification dynamics in mother and daughter cells. *Methods* 70, 77–88.

Strzyz, P.J., Lee, H.O., Sidhaye, J., Weber, I.P., Leung, L.C., and Norden, C. (2015). Interkinetic nuclear migration is centrosome independent and ensures apical cell division to maintain tissue integrity. *Dev Cell* 32, 203–219.

Svaren, J., Klebanow, E., Sealy, L., and Chalkley, R. (1994). Analysis of the competition between nucleosome formation and transcription factor binding. *J Biol Chem* 269, 9335–9344.

Tadros, W., and Lipshitz, H.D. (2009). The maternal-to-zygotic transition: a play in two acts. *Development* 136, 3033–3042.

Tan, M.H., Au, K.F., Yablonovitch, A.L., Wills, A.E., Chuang, J., Baker, J.C., Wong, W.H., and Li, J.B. (2013). RNA sequencing reveals a diverse and dynamic repertoire of the *Xenopus tropicalis* transcriptome over development. *Genome Research* 23, 201–216.

Vasseur, P., Tonazzini, S., Ziane, R., Camasses, A., Rando, O.J., and Radman-Livaja, M. (2016). Dynamics of Nucleosome Positioning Maturation following Genomic Replication. *CellReports* 16, 2651–2665.

Vastenhouw, N.L., Zhang, Y., Woods, I.G., Imam, F., Regev, A., Liu, X.S., Rinn, J., and

Schier, A.F. (2010). Chromatin signature of embryonic pluripotency is established during genome activation. *Nature* *464*, 922–926.

Veenstra, G.J., Destrée, O.H., and Wolffe, A.P. (1999). Translation of maternal TATA-binding protein mRNA potentiates basal but not activated transcription in *Xenopus* embryos at the midblastula transition. *Molecular and Cellular Biology* *19*, 7972–7982.

Weidinger, G., Stebler, J., Slanchev, K., Dumstrei, K., Wise, C., Lovell-Badge, R., Thisse, C., Thisse, B., and Raz, E. (2003). dead end, a novel vertebrate germ plasm component, is required for zebrafish primordial germ cell migration and survival. *Curr Biol* *13*, 1429–1434.

Woodland, H.R., and Adamson, E.D. (1977). The synthesis and storage of histones during the oogenesis of *Xenopus laevis*. *Developmental Biology* *57*, 118–135.

Worboys, J.D., Sinclair, J., Yuan, Y., and Jørgensen, C. (2014). Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome. *Nat Meth* *11*, 1041–1044.

Yang, J. (2002). beta-Catenin/Tcf-regulated transcription prior to the midblastula transition. *Development* *129*, 5743–5752.

Yartseva, V., and Giraldez, A.J. (2015). The Maternal-to-Zygotc Transition During Vertebrate Development: A Model for Reprogramming. *Curr. Top. Dev. Biol.* *113*, 191–232.

Zamir, E., Kam, Z., and Yarden, A. (1997). Transcription-dependent induction of G1 phase during the zebra fish midblastula transition. *Molecular and Cellular Biology* *17*, 529–536.

Zaret, K.S., and Carroll, J.S. (2011). Pioneer transcription factors: establishing competence for gene expression. *Genes & Development* *25*, 2227–2241.

Zhang, Y., Vastenhouw, N.L., Feng, J., Fu, K., Wang, C., Ge, Y., Pauli, A., van Hummelen, P., Schier, A.F., and Liu, X.S. (2014). Canonical nucleosome organization at promoters forms during genome activation. *Genome Research* *24*, 260–266.

## FIGURE LEGENDS

**Figure 1. Assay to analyze the onset of transcription in zebrafish.** **A.** In zebrafish, transcription begins ~3 hours post fertilization. Stage-specific drawings of representative embryos are adapted from (Kimmel et al., 1995) with permission (from CB Kimmel, permission from Wiley is pending). **B.** Expression of six genes was analyzed by qPCR at 512-cell, early 1K, mid 1K, high and oblong stage in wild-type embryos. Inset shows the same data, focusing on 1K and high stage. Data was taken from Figure 2B and 3D. Error bars represent SEM ( $n \geq 4$ ). **C.** Cell counting of DAPI-stained nuclei imaged with a 2-photon microscope. Multiple z-slices and four tiles were stitched to allow rendering in imaging software Imaris and the calculation of cell number. Image shown is a representative example of high stage. Scale bar, 100  $\mu\text{m}$ . **D.** Quantification of the number of cells at 1K, high, oblong, sphere and dome stage. Each data point represents a biological replicate consisting of three embryos. Error bars represent SEM ( $n=3$ ). **E.** Western blots showing the protein level of histone H3, H4, H2A, and H2B in embryos at 8-cell, 64-cell, 256-cell and 1K stage. Tubulin was used to control for equal loading in each experiment. Blots shown are representative examples ( $n > 3$ ).

**Figure 2. Increasing the levels of all core histones delays onset of transcription and gastrulation.** **A.** Schematic representation of experimental procedure. Histone cocktail (HC) containing ~5800 genomes worth of histones, or BSA was injected into the yolk of 1-cell embryos and qPCR and NanoString analysis was carried out at stages around genome activation. Orange crosses represent the timing of stages used for the analysis. **B.**

Expression of *mxtx2* and *fam212aa* was analyzed by qPCR at early 1K, high, and oblong stage in uninjected, BSA-injected and HC-injected embryos. Bar graphs show the same data, focusing on high stage. Error bars represent SEM ( $n \geq 13$ ). \*\*\* $P < 0.001$  (two-tailed Student's t test, compared to BSA control). **C.** Expression of 53 zygotically expressed genes was analyzed by NanoString analysis at high stage in uninjected, BSA-injected and HC-injected embryos. Mean counts of three independent biological replicates are shown. Location of *mxtx2* and *fam212aa* counts is indicated (See Figure 2-figure supplement 2 for more details). **D.** Relative expression level of *mxtx2* and *fam212aa* at high stage, for embryos injected with BSA, HC, and HC minus H3, H4, H2A, or H2B. Error bars represent SEM ( $n=7$ ). \*\*\* $P < 0.001$  (Ordinary one-way ANOVA). **E.** Brightfield images of embryos that were not injected, injected with BSA, or injected with HC. Boxed images represent the onset of gastrulation. Scale bar shown for the uninjected 2-cell embryo applies to all treatments except for 24 hpf embryos which have a different scale bar. All scale bars represent 250  $\mu\text{m}$ . hpf, hours post fertilization. **F.** Bar graph shows the quantification of the extra time it takes embryos to start gastrulation upon injecting BSA, HC, or HC minus one histone, compared to uninjected embryos. Error bars represent SEM ( $n=27$  for BSA,  $n=25$  for HC,  $n=7$  for HC minus one histone experiments). \*\*\* $P < 0.001$  (Ordinary one-way ANOVA with Tukey's multiple comparison test). In B and D, mRNA levels are normalized to the expression of *EIF4G2A*.

**Figure 3. Decreasing the level of histones causes premature transcription. A.** Schematic representation of experimental procedure. *ptx3-rfp* or *rfp* (control) mRNA was injected into the cell of 1-cell embryos and qPCR analysis was carried out at stages

around genome activation. Orange crosses represent the timing of stages used for the analysis. **B.** Western blot analysis of PTX3, histone H3 and H4 levels at 512-cell, 1K and high stage in uninjected embryos, *rfp* and *ptx3-rfp* mRNA-injected embryos. Tubulin was used to control for equal loading. Blots shown are representative examples (n=3). **C.** Western blot analysis for histone H4 after a pull-down using an RFP antibody at 1K stage. Uncoupled beads were used as a negative control. Blot shown is a representative example (n=3). **D.** Expression of *mxtx2* and *fam212aa* was analyzed by qPCR at 512-cell, early 1K, and mid 1K stage in uninjected, *rfp* mRNA-injected and *ptx3-rfp* mRNA-injected embryos. Bar graphs focus on early 1K stage. Error bars represent SEM (n≥4). \*P<0.05; \*\*P<0.01 (two-tailed Student's t test, compared to *rfp* mRNA control). mRNA levels are normalized to the expression of *EIF4G2A*.

**Figure 4. Onset of transcription coincides with a reduction in nuclear histone concentration.** **A.** Our quantitative mass spectrometry approach. Zebrafish histones were quantified by comparing the abundances of native histone peptides with corresponding isotopically labeled peptides from the chimeric protein; chimeric protein was quantified by comparing the abundance of labeled (from chimera) and native (from standard) BSA peptides (see Materials and Methods for more details). **B.** Quantification of the number of histone H3, H4, H2A, and H2B per embryo at indicated stages by quantitative mass spectrometry. Error bars represent SEM (n=3). **C.** The excess number of histones per cell (in genomes worth) was calculated using H2B levels (Figure 4-source data 1) and cell numbers (Figure 1-source data 1), and by assuming an average of 1.5 genomes per cell (see Materials and Methods for more details). For better visualization of the data at later

developmental stages the values for 1-cell and 8-cell are not shown in the graph but are 3098 and 518, respectively. Error bars represent SEM (n=3). GW, genomes worth of histones. **D.** The total concentration of non-DNA bound histones was calculated by dividing the excess genomes worth of histone H2B per embryo by the volume of the animal cap at the respective stages (Figure 4-figure supplement 1A). Error bars represent SEM of animal cap volumes (n=3). GW, genomes worth of histones. **E.** The nuclear concentration of non-DNA bound histones was calculated from immunofluorescence (from left to right n=12, 12, 14, 15) combined with live imaging and mass spectrometry data (see Materials and Methods for more details). Error bars represent SEM of animal cap volumes (n=3). **F.** Relative differences in H2B intensity between chromatin fractions of 256-cell, 512-cell, 1K, and high stage embryos. Sphere stage embryos were used to determine the linear range of H2B detection (see also figure 4-figure supplement 1C). Blots shown are representative examples (n≥3). Plots show observed fold differences in H2B intensity in chromatin fractions comparing indicated stages compared to the differences that would be expected if the intensity were to scale with the amount of DNA (E, embryo). **G.** Competition model. See text for more details (TFBS, transcription factor binding site).

**Figure 5. Direct experimental evidence for the competition model using endogenous genes and transcription factors.** **A.** Schematic representation of experimental procedure. Pou5f3 levels were decreased by injecting a morpholino, or increased by injecting *pou5f3* mRNA (in combination with *sox19b* mRNA) into the cell of 1-cell embryos. Controls used were a Dead-end morpholino and *gfp* mRNA, respectively. qPCR

and CHIP-qPCR analysis was carried out at stages around genome activation. Orange crosses represent the timing of stages used for the analysis. **B.** Expression of *apoeb* and *dusp6* was analyzed by qPCR at 512-cell, early 1K, mid 1K and high stage in control and Pou5f3 morpholino-injected embryos. The data in the bar graphs focus on the mid 1K stage. Error bars represent SEM ( $n \geq 4$ ). \* $P < 0.05$  (two-tailed Student's t test, compared to control MO). **C.** Expression of *apoeb* and *dusp6* was analyzed by qPCR at 512-cell, early 1K and high stage in uninjected embryos, embryos injected with control mRNA and embryos injected with *pou5f3* and *sox19b* mRNA. Bar graphs focus on the early 1K stage. Error bars represent SEM ( $n \geq 4$ ). \*\* $P < 0.01$  (two-tailed Student's t test, compared to control mRNA). **D.** Binding of Pou5f3 to its respective binding sites for *apoeb* and *dusp6* (Leichsenring et al., 2013) and control region was analyzed by CHIP-qPCR at the early 1K stage in embryos injected with *pou5f3* + *sox19b* mRNA or *pou5f3* + *sox19b* mRNA plus histone cocktail. Enrichment of pulled-down fragments was normalized to input. Location of primer sets in respect to the transcription start-site used for CHIP-qPCR analysis are indicated by arrows. A genome control region on chromosome 23 was also used. Error bars represent SEM ( $n = 5$ ). \*\* $P < 0.01$  (two-tailed Student's t test ratio paired, compared to *pou5f3* + *sox19b* mRNA-injected embryos). In B and C, mRNA levels are normalized to the expression of *eif4g2a*.

**Figure 6. Direct experimental evidence for the competition model using a heterologous transgene.** **A.** Schematic representation of the experimental procedure and TRE:GFP transgene. tTA-VP16 and/or histone levels were increased by injecting mRNA or HC into the cell or yolk, respectively, of 1-cell transgenic embryos. The TRE element

contains seven binding sites for tTA-VP16 and is joined to a CMV promoter. qPCR and ChIP-qPCR analysis was carried out at stages around genome activation. Orange crosses represent the timing of stages used for the analysis. **B.** Expression of *gfp* was analyzed by qPCR at 512-cell, early 1K and high stage in embryos injected with 5 or 300 pg *tTA-VP16* mRNA. Bar graphs focus on the early 1K stage. Error bars represent SEM (n≥4). \*P<0.05 (two-tailed Student's t test, compared to 5 pg *tTA-VP16* mRNA). **C.** Expression of *gfp* was analyzed by qPCR at early 1K stage in embryos injected with 5 pg, 300 pg *tTA-VP16* mRNA and 300 pg *tTA-VP16* mRNA plus histone cocktail. Error bars represent SEM (n=4). \*P<0.05 (Ordinary one-way ANOVA). **D.** Binding of tTA-VP16 to the TRE element and control regions was analyzed by ChIP-qPCR at the early 1K stage in embryos injected with 300 pg *tTA-VP16* mRNA or 300 pg *tTA-VP16* mRNA plus histone cocktail. Enrichment of pulled-down fragments was normalized to input. Primer sets used for ChIP-qPCR analysis are indicated by arrows in panel A. A control region on the transgene was used in addition to a genome control region on chromosome 23. Error bars represent SEM (n=3). \*P<0.05 (two-tailed Student's t test ratio paired, compared to 300 pg *tTA-VP16* mRNA-injected embryos). In B and C, mRNA levels are normalized to the expression of *eif4g2a*.

**Figure 1-source data 1. Cell numbers for wild-type zebrafish embryos.** At every stage, cells were counted for three biological replicates, each consisting of three embryos.

**Figure 2-source data 1. NanoString probe set.**

**Figure 4-source data 1. Quantification of histone number by mass spectrometry.** See Materials and Methods for details on calculations.

## SUPPLEMENTAL FIGURE LEGENDS

### **Figure 1-figure supplement 1. Selection of genes and *eif4g2a* as a normalizer gene.**

**A.** Schematic representation of gene-selection procedures. **B.** Maternally loaded *eif4g2a* mRNA was used as a control in qPCR analyses. To test whether the level of *eif4g2a* mRNA was stable during the stages of interest (not degraded and independent of zygotic transcription), the level of *eif4g2a* mRNA was analyzed in wild-type embryos and in embryos that were injected with the transcription inhibitor  $\alpha$ -amanitin. As a control, *sox19a* mRNA was analyzed. Indicated are the Ct's (threshold cycles in quantitative PCR analysis) for *eif4g2a* and *sox19a* as obtained at 512-cell, early 1K, high, oblong and late oblong in the presence (minus  $\alpha$ -amanitin) and absence (plus  $\alpha$ -amanitin) of zygotic transcription. Whereas the Ct's for *sox19a* decrease starting at high stage (green), the Ct's for *eif4g2a* do not (red). Moreover,  $\alpha$ -amanitin inhibits the transcription of *sox19a* (black) but does not affect the levels of *eif4g2a* (blue). Together, this shows that *eif4g2a* is neither degraded nor zygotically transcribed during the stages we analyzed. Shown is a representative example of two replicates.

### **Figure 2-figure supplement 1. Increasing the levels of all core histones delays onset**

**of transcription.** **A.** Expression of *nnr*, *vox*, *sox19a*, and *grhl3* was analyzed by qPCR at early 1K, high, and oblong stage in uninjected, BSA-injected and HC-injected embryos. Bar graphs show the same data, focusing on high stage. Error bars represent SEM ( $n \geq 13$ ). \*\*\* $P < 0.001$  (two-tailed Student's t test, compared to BSA control). **B.** Staging by morphology was verified by cell counting. Each data point represents a single embryo.

Error bars represent SEM. **C.** Confocal microscope images of transgenic fish line Tg(h2afz:h2afz-GFP) injected with Cy5 conjugated to H4. Arrow points at chromatin in dividing cell. Scale bar, 20  $\mu$ m. **D.** Relative expression level of *nnr*, *vox*, *sox19a*, and *grhl3* at high stage, for embryos injected with BSA, HC, and HC minus H3, H4, H2A, or H2B. Error bars represent SEM (n=7). \*P<0.05; \*\*P<0.01; \*\*\*P<0.001 (Ordinary one-way ANOVA). In A and D, expression is normalized to the expression of *eif4g2a*.

**Figure 2-figure supplement 2. Increasing the levels of all core histones delays onset of transcription for a large number of genes.** NanoString's nCounter technology was used to analyze changes in gene expression upon HC injection for a large number of genes (see Materials and Methods for more details). From a custom probe set with 84 zygotically expressed genes and 12 controls genes (see Figure 2-source data 1), 53 genes that are induced at high stage were used for analysis. mRNA was collected from high stage embryos that were uninjected, BSA-injected and HC-injected (n=3). **A.** Fold difference in expression of twelve control genes, for embryos injected with BSA or HC compared to uninjected. Control genes are maternally provided and were previously shown to be stable from 512-cell to dome stage in NanoString analysis (data not shown). Error bars represent SEM (n=3). No significant difference was detected between BSA or HC-injected in control genes (Ordinary one-way ANOVA with Tukey's multiple comparison test), showing that there are no differences in total RNA amount between samples. **B.** Proportion of genes affected by BSA or HC injection at high stage in NanoString analysis. Error bars represent SEM (n=3). A large proportion of genes are down regulated in HC-injected embryos (86%) compared to BSA-injected embryos (4%).

C. Mean counts of three independent biological replicates in NanoString analysis for uninjected, BSA-injected and HC-injected embryos compared to a high (left) and 1K (right) standard from uninjected embryos. While uninjected and BSA-injected are statistically similar to the high standard, HC-injected is statistically similar to the 1K standard. Thus, HC-injected embryos that are developmentally at high stage, are transcriptionally delayed by one developmental stage. Error bars represent SEM (n=3). \*\*\*P<0.001 (Ordinary one-way ANOVA with Tukey's multiple comparison test). **D.** Fold difference in mRNA counts for HC-injected and BSA-injected compared to uninjected embryos at high stage for all genes that were analyzed by qPCR in this study. Error bars represent SEM (n=3). \*P<0.05; \*\*P<0.01; \*\*\*P<0.001 (two-tailed Student's t test ratio paired, compared to BSA-injected).

**Figure 3-figure supplement 1. Decreasing the level of histones causes premature transcription.** **A.** Expression of *nnr*, *vox*, *sox19a*, and *grhl3* was analyzed by qPCR at 512-cell, early 1K and mid 1K in uninjected embryos, embryos injected with *rfp* (control) mRNA and embryos injected with *ptx3-rfp* mRNA. Bar graphs show the same data, focusing on early 1K stage. Error bars represent SEM (n≥4). n.s. P>0.05; \*P<0.05; \*\*P<0.01 (two-tailed Student's t test, compared to *rfp* mRNA control). Expression is normalized to the expression of *eif4g2a*. **B.** Staging by morphology was verified by cell counting at the stages used for the analysis. Each data point represents a single embryo. Error bars represent SEM.

**Figure 4-figure supplement 1. Onset of transcription coincides with a reduction in nuclear histone concentration.** **A.** Changes in total animal cap volume, the fraction of the animal cap volume occupied by nuclei, and the size of individual nuclei for indicated stages. Volumes were measured by lightsheet microscopy of embryos injected with mRNA encoding H4-sfGFP and subsequent automated image analysis (error bars represent SEM, n=3 embryos; offspring of transgenic PCNA-RFP was used to monitor integrity of imaged nuclei via a second color channel). **B.** Image sequences showing nuclear import of H4-sfGFP fusion protein at 32- 64- and 128-cell stage. Color scaling was kept constant and linear within each stage. Images show a representative maximum z-projection of a subset of a 3D microscopy stack of one of the embryos used in A. **C.** The linear range of Western blots was determined using chromatin of sphere-stage embryos. Plotted are observed versus expected fold differences in H2B intensity using different numbers of embryos (n $\geq$ 3). Band intensities of test stages (Figure 4F) were only used for the analysis when they fell within the linear range.

**Figure 5-figure supplement 1. Reducing transcription factor levels delays the onset of transcription.** **A.** Pou5f3 morpholino validation. Brightfield images of embryos that were injected with control or Pou5f3 morpholino. Embryos injected with Pou5f3 morpholino arrested at sphere or dome stage, as reported previously (Burgess et al., 2002). Scale bar, 250  $\mu$ m. Western blot of embryos injected with 50 ng *pou5f3*-2xHA mRNA alone or in combination with 6 ng Pou5f3 morpholino. As expected, the morpholino reduces the expression of Pou5f3. **B.** We injected embryos with Pou5f3 morpholino and analyzed the effect on transcription. Shown are the fold changes in relative expression levels of Pou5f3-morpholino-injected embryos compared to control

morpholino-injected embryos at high stage for Pou5f3 targets *apoeb*, *dusp6*, *klf17*, *irx7*, and *klf2b*, and non-Pou5f3 targets *sox19a*, *grhl3* and *gadd45bb*. Reduction of Pou5f3 results in decreased transcription for all Pou5f3 target genes analyzed at high stage, confirming that they are regulated by Pou5f3. Non-targets were not affected. Error bars represent SEM (n=4). n.s. P>0.05; \*P<0.05; \*\*P<0.01; \*\*\*P<0.001 (two-tailed Student's t test, compared to control morpholino). **C.** Expression of *klf17*, *irx7* and *klf2b* was analyzed by qPCR at 512-cell, early 1K, mid 1K and high stage in control and Pou5f3 morpholino-injected embryos. Bar graphs focus on mid 1K stage. Error bars represent SEM (n≥4). \*\*P<0.01; \*\*\*P<0.001 (two-tailed Student's t test, compared to control morpholino). **D.** Western blot analysis of embryos injected with *sox19b*-2xHA mRNA alone and in combination with 2ng of Sox19b morpholino validate the effect of the Sox19b morpholino. **E.** Expression of *dusp6* was analyzed by qPCR at 512-cell, early 1K, mid 1K and high stage in control and Sox19b morpholino-injected embryos. *dusp6* was selected for analysis because it is the only gene from our selected Pou5f3-target genes that is also regulated by SoxB1 (Lee et al., 2013). Error bars represent SEM (n≥4). **F.** Validation of FoxH1 target genes. To verify that the genes we selected require FoxH1 for their expression, we injected embryos with FoxH1 morpholino and analyzed the effect on transcription. Shown are the fold changes in relative expression levels of FoxH1 morpholino-injected embryos compared to control morpholino-injected embryos at high stage for FoxH1 targets *dusp6*, *flh*, *wnt11* and *gadd45bb*. Reduction of FoxH1 results in decreased transcription for all FoxH1 target genes. **G.** Expression of *dusp6*, *flh*, *wnt11* and *gadd45bb* was analyzed by qPCR at 512-cell, early 1K, mid 1K and high stage in control and FoxH1 morpholino-injected embryos. All four target genes show a delay in

the time when they are first transcribed in the FoxH1 morphants compared to control morpholino-injected embryos. Error bars represent SEM ( $n \geq 4$ ). **H.** Staging by morphology was verified by cell counting at the stages used for the Pou5f3 morpholino analysis. Each data point represents a single embryo. Error bars represent SEM. Gene expression is normalized to the expression of *eif4g2a*.

**Figure 5-figure supplement 2. Increasing transcription factor levels causes premature transcription.**

**A.** Pou5f3 overexpression validation. Brightfield images of embryos that were injected with control or *pou5f3* mRNA. Developmental defects at 24 hpf resembled the ventralized phenotypes described upon *pou5f3-VP16* overexpression (Belting et al., 2011). Scale bar, 250  $\mu$ m. Western blot using an HA antibody shows the protein level of Pou5f3-2xHA and Sox19b-2xHA in embryos at 1K stage after injection at the 1-cell stage. Blot shown is a representative example ( $n=2$ ). **B.** To test whether Pou5f3 and Sox19b are sufficient to drive expression of the genes we selected, we increased the level of both transcription factors and analyzed the effect on transcription. Shown are the expression levels of *apoeb*, *dusp6*, *klf17*, *irx7*, and *klf2b* at high stage for embryos injected with *pou5f3* + *sox19b* mRNA relative to control mRNA-injected. Error bars represent SEM ( $n \geq 4$ ). Increasing the levels of Pou5f3 and Sox19b only increased the relative expression level of *apoeb* and *dusp6*, suggesting that Pou5f3 and Sox19b are not sufficient to drive expression of the other genes. Error bars represent SEM ( $n \geq 4$ ). n.s  $P > 0.05$ ; \* $P < 0.05$  (two-tailed Student's t test, compared to control mRNA). **C.** Expression of *klf17*, *irx7* and *klf2b* and was analyzed by qPCR at 512-cell, early 1K, and high stage

in uninjected, control and *pou5f3* + *sox19b* mRNA-injected embryos. Bar graphs focus on the early 1K stage. Error bars represent SEM (n≥4). n.s P>0.05 (two-tailed Student's t test, compared to control mRNA). **D.** Staging by morphology was verified by cell counting at the stages used for the analysis. Each data point represents a single embryo. Error bars represent SEM. In B and C, expression is normalized to the expression of *EIF4G2A*.

**Figure 6-figure supplement 1. Direct experimental evidence for the competition model using a heterologous transgene.** **A.** Western blot using an HA antibody shows the protein level at 1K stage after injection of either 5 pg or 300 pg *tTA-VP16* mRNA. Tubulin was used to control for equal loading. Blot shown is a representative example (n=2). **B.** Binding of tTA-VP16 to the TRE element was analyzed by ChIP-qPCR at the early 1K stage in embryos injected with 300 pg *tTA-VP16* or 300 pg *tTA-VP16* mRNA plus histone cocktail. Enrichment of pulled-down fragments was normalized to input. All primers used for ChIP-qPCR are indicated using arrows. Error bars represent SEM (n=3). \*P<0.05 (two-tailed Student's t test ratio paired, compared to 300 pg *tTA-VP16* mRNA plus histone cocktail).

**Movie 1.** Two channel recording of H4-sfGFP and PCNA-RFP distributions from 8-cell to oblong stage. H4-sfGFP (left, green channel) intensities are transformed to logarithmic scale to compensate for intensity increase due to ongoing translation of mRNA into fluorescent fusion protein. PCNA-RFP (right, magenta channel) intensities are linear.

Both channels are maximum z-projections, with a view upon the animal cap, time stamps are given in hour:minute format, starting with the first acquired frame.


**Table 1. List of morpholinos used.**

**Table 2. List of primers used.**


**Table 3. List of primary antibodies used.**

**Table 4. List of secondary antibodies used.**


## Figure 1




## Figure 2




## Figure 3



## Figure 4



## Figure 5



## Figure 6




Table 1

**List of morpholinos used**

<b>Morpholinos</b>			
<b>Target</b>	<b>Sequence</b>	<b>Company</b>	<b>Reference</b>
<b>p53</b>	5'-GCGCCATTGCTTTGCAAGAATTG	GeneTools	Langheinrich et al., 2002
<b>Pou5f3</b>	5'-CGCTCTCTCCGTCATCTTTCCGCTA	GeneTools	Burgess et al., 2002
<b>Sox19b</b>	5'-ACGAGCGAGCCTAATCAGGTCAAAC	GeneTools	Okuda et al., 2010
<b>Foxh1</b>	5'-TGCTTTGTCATGCTGATGTAGTGGG	GeneTools	Pei et al., 2007
<b>Dead-end</b>	5'-GCTGGGCATCCATGTCTCCGACCAT	GeneTools	Weidinger et al., 2003
<b>Ctrl MO</b>	5'-CCTCTTACCTCAGTTACAATTTATA	GeneTools	GeneTools, LLC

Table 2

## List of primers used

Primer list	
Gene	Primers
<i>EIF4G2A</i>	5'-GAGATGTATGCCACTGATGAT
	5'-GCGCAGTAACATTCCCTTTAG
<i>MXTX2</i>	5'-ACTGACTGCATTGCTCAA
	5'-ACCATACCTGAATACGTGATT
<i>FAM212AA</i>	5'-GCAAATGAGTATCTAAAAGTCT
	5'-CATCATATAGCGCATCTGGT
<i>NNR</i>	5'-GAGACATACCACAGGTGAAGC
	5'-CCGCTCTGGTCTGTTGC
<i>VOX</i>	5'-TTATTTCGTCGGGTTATGAGAG
	5'-AACCAAGTTCTGATCTGTGT
<i>SOX19A</i>	5'-GAGGATGGACAGCTACGG
	5'-CTATAGGACATGGGGTTGTAG
<i>GRHL3</i>	5'-AGACGAGCAGAGAGTCCT
	5'-TTGCTGTAATGCTCGATGATG
<i>POEB</i>	5'-GAGACAGCTTTCACACGCTAA
	5'-TGCATTCTGCTCCATCATG
<i>DUSP6</i>	5'-AGCCATCAGCTTTATTGATGAG
	5'-CAAAGTCCAAGAGTTGACCC
<i>KLF17</i>	5'-ATAGTTCGGGACTGGAAAGTTG
	5'-TGAGGTGTTGTCGTTGTGTCAG
<i>IRX7</i>	5'-TGGCACACATTAGCAATTCC
	5'-GCATGATCTTCTCGCCTTTG
<i>KLF2B</i>	5'-GCTCTGGGAGGATAGATGGA
	5'-CTCGGAGTGGGAGATGAAC
<i>FLH</i>	5'-CACTGAAGCTCAGGTTAAAGTC
	5'-ACAATCTGGGGAAAATCATGG
<i>WNT11</i>	5'-CAGACAGGTGCTTATGGACT
	5'-CATCTCTCGGGGCACAAG
<i>GADD45BB</i>	5'-CAACTCATGAATGTGGATCCAG
	5'-ATGCAGTGAAGGTCTCTTGG
<i>GFP</i>	5'-GCACCATCTTCTTCAAGGAC
	5'-TTGTCGGCCATGATATAGAC
<b>Pou5f3 binding site (-2270 <i>apoeb</i>)</b>	5'-TAAAGTGAGCAAATGTATGGCC
	5'-TTTGTGATTAAATCGCTTGTGA
<b>Pou5f3 binding site (-3095 <i>dusp6</i>)</b>	5'-CATATGTTAAGCGGGGTGAAAC
	5'-ATCCTGTCTCCTGTGTCATTTG
<b>TRE binding site (-222)</b>	5'-TCTTGATAGAGAGGCTGCAAAT
	5'-TCGAGATGGGCCCTTGATA
<b>TRE binding site (13)</b>	5'-TCGTATAGGGATAACAGGGTAATG
	5'-TACACGCCTACCTCGACC
<b>TRE binding site (217)</b>	5'-GTACGGTGGGAGGCCTATAT
	5'-CTTCTATGGAGGTCAAAACAGC
<b>transgene control</b>	5'-CTCTACAAATGTGGTATGGCTG
	5'-ATTACCCTGTTATCCCTAAGGC
<b>genomic control</b>	5'-CCATCATATTCACATCTTGCAAG
	5'-GTTTCGTATGAACCGGAAGC

bioRxiv preprint doi: <https://doi.org/10.1101/125140>; this version posted April 13, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.

Table 3

**List of primary antibodies used**

[WB] Western blotting, [IF] immunofluorescence, [IP] immunoprecipitation.

Primary antibodies						
Target/Name	Company	Company code	RRID	[WB]	[IF]	[IP]
H3	Abcam	ab1791	AB_302613	1:10,000		
H4	Abcam	ab10158	AB_296888	1:1,000	1:300	
H2A	Abcam	ab18255	AB_470265	1:1,000		
H2B	Abcam	ab1790	AB_302612	1:3,000		
$\alpha$ -tubulin	Sigma	T6074	AB_477582	1:20,000		
RFP	Abcam	ab152123	AB_2637080			Excess
PTX3	Cosmo Bio	PPZ1724	AB_1962280	1:15,000		
RNA Pol II	BioLegend	MMS-126R	AB_10013665		1:1,000	
HA	Abcam	ab9110	AB_307019	1:5,000		Excess
IgG from rabbit serum	Sigma	I5006	AB_1163659			Excess

Table 4

**List of secondary antibodies used**

Secondary antibodies					
Name	Company	Company code	RRID	[WB]	[IF]
Alexa 488 goat anti-mouse IgG H&L	ThermoFisher	A-11029	AB_138404		1:1,000
Alexa 594 goat anti-rabbit IgG H&L	ThermoFisher	A-11037	AB_2534095		1:500
IRDye 800CW donkey anti-rabbit IgG H&L	LI-COR	P/N 926-32213	AB_621848	1:20,000	
IRDye 800CW donkey anti-mouse IgG H&L	LI-COR	P/N 926-32212	AB_621847	1:20,000	
Peroxidase AffiniPure goat anti-rabbit IgG H&L	Jackson ImmunoResearch	111-035-144	AB_2307391	1:20,000	
Peroxidase AffiniPure rabbit anti-mouse IgG H&L	Jackson ImmunoResearch	315-035-003	AB_2340061	1:20,000	

## Figure 1—source data 1

### Cell numbers for wild-type zebrafish embryos

	Biological replicate number		
	1	2	3
<b>1K</b>	984	1054	1015
	1008	1011	1019
	1042	1039	1026
<b>high</b>	1738	1988	2063
	1665	1799	1961
	1879	1939	2061
<b>oblong</b>	3101	3090	3461
	3384	2654	3352
	3228	3311	3360
<b>sphere</b>	3721	3779	4137
	4171	3647	3773
	3847	3718	4166
<b>dome</b>	6536	6971	6861
	7116	6963	6603
	6790	6766	7272

Figure 2—source data 1

**NanoSting probe set**

An RNA-seq data set was used to select control genes based on stable expression between 2-4-cell and shield stage, and zygotic genes based on minimal maternal contribution and strong induction during genome activation (Pauli et al., 2012). A developmental time series from 512-cell to dome using NanoString confirmed that all control genes were stable and zygotic genes were induced at appropriate stages (data not shown). The *htafx* gene was removed from the analysis due to unrealistically high count values.

Gene name	Accession	Position	Target Sequence	HUGO Gene	NSID	Gene category
<i>bcap29</i>	ENSDART0000007638.2	717-816	GCTCTGAAAAAGTCAAAGTCTGATTTAGACACCATGAAGAAACAAAGTGACGGACTGACCAAAGAGTACGAGCGGCTGCTTCAGGAGCACCAGCAGCTGC	ENSDARG00000016231	ENSDART00000007638.2:716	Control
<i>ehd3</i>	ENSDART00000022694.2	1092-1191	GGCACACGATCTAAACAAGTTCAGCCTCTAAAAATGAAGCTTTTGGACACTGTGGATGATATGCTGGCCCATGACATCGCCCAACTTATGGTTCTGGTG	ENSDARG00000007869	ENSDART00000022694.2:1091	Control
<i>EIF4G2A</i>	ENSDART00000027616.2	1493-1592	GGGCAGAACCTGCTTTTCCAAAACCAGACTCATTCTCAACAGCAAGCTCAGTCTAAGGATATGCCACCAGTTTCACTAAGAAAGGACAGCTGAATG	ENSDARG00000020377	ENSDART00000027616.2:1492	Control
<i>paf1</i>	ENSDART00000064444.2	156-255	GAAGGTGGAAGTCAAGATCGGTGTGTCGTCAAGCAGCAGTTCACAGAGGAGGAGATCTATAAAGACAGAGACAGTCAGATCGCTGCCATTGAGAAGACC	ENSDARG00000043886	ENSDART00000064444.2:155	Control
<i>PHYKPL</i>	ENSDART00000059369.2	790-889	GTAGCAGAATATGTTTCATGAAGCAGGAGGGGTTTATGTGGCAGATGAGATTCAGACAGGCTTTGGTCTGTGGGAGTCATTTCTGGGCGTTTCAGCTTG	ENSDARG00000040566	ENSDART00000059369.2:789	Control
<i>prcc</i>	ENSDART00000092265.2	537-636	CACAGAGCCCGTGAATAATCATCGTTCCTCAATAAAACCCGACAGATTCGGACTCTGATGATGATGAGCCAGTGCAGAAAGAAATCAGTCTCTCGGGGACAGT	ENSDARG00000063252	ENSDART00000092265.2:536	Control
<i>qrch1</i>	ENSDART00000040171.2	1413-1512	AATGAACAAAATAAGCTGGCACCTATTGGACGTCGACAGCCGCTGCGCTTCCAGGACGATCTTGTGTCGAGTTCAGTGGGAGAGTTGAACCTGGCTCTGT	ENSDARG00000019797	ENSDART00000040171.2:1412	Control
<i>RNA binding motif 1</i>	ENSDART00000066084.2	1655-1754	GATTCCTCAAAGAAACCCTGGTTTGACAAACCGAACTTCAGCAAACCAATCACCACGGCTTTCACAGAAAAGTGCCTTCCCTTTAGCAAACACCAAA	ENSDARG00000018889	ENSDART00000066084.2:1654	Control
<i>rmmt</i>	ENSDART00000088917.2	691-790	AGAGCGAGTCGCAGGCTGACACCATGCTGAGAAATGCCTGTGAGAGACTCCGGCCTGGAGGATTCTTCATCGGGACAACCTCTGATGCATATGAGCTGGT	ENSDARG00000070553	ENSDART00000088917.2:690	Control
<i>sec31a</i>	ENSDART00000108587.2	1096-1195	GTGTTTCGATATCCAGTGGTGCCCAAGAAACCCAGCTGTTCTGTCTGCTGCTTTTGTATGGCCACATCAGTATCTACTCCATTATGGGAGGAAGCAAT	ENSDARG00000021082	ENSDART00000108587.2:1095	Control
<i>UBE2Q</i>	ENSDART00000016117.2	297-396	TCACTGCAACATCACGGAGTCTTATCCTTCAACACCACCAATATGGTTTGTGATTCTGATGATCCAAGTCTGACTGAAGTCCTTGAGCGACTGGAGGAT	ENSDARG00000013990	ENSDART00000016117.2:296	Control
<i>yap1</i>	ENSDART00000098914.2	1296-1395	CACCCAAAACCCTGTGTCTTCACTGGTATGGGCCAAGACGCCGTAACATGACCACCAACAGCTCTGACCCTTCTTGAACAGCGGGACATATCACTCT	ENSDARG00000068401	ENSDART00000098914.2:1295	Control
<i>admp</i>	ENSDART00000037557.2	969-1068	GCAAAAAAACGCTCTCGAAGGGAAGAAGCTGCTCTCATCCAGACTGGTTCCAATTCAGTCTACTGGCTGGGAGGTTTTTACCATCACTCAAGCTGTGCG	ENSDARG00000025372	ENSDART00000037557.2:968	ZGA gene
<i>akap12b</i>	ENSDART00000110883.2	356-455	GAGAAGGGAGACGATTCTGCAATGCAGATGAGATTACAACCTGCTGAAGAGAAGGTGGTAGAGGAAAAACAAGAAGAGGCCAATGAAGTGGGCTTCAAGA	ENSDARG00000055678	ENSDART00000110883.2:355	ZGA gene
<i>aldob2</i>	ENSDART00000139865.2	191-290	ATGAATCCACAGGCACCATGGCGAAGCGTTTCCAGAAGATAAATGTAGAGAACTGAAGAAAATCGCCGTAGCTTTCGCGACCTTCTTCTCAGTAGA	ENSDARG00000053684	ENSDART00000139865.2:190	ZGA gene
<i>aplnrB</i>	ENSDART00000129643.2	1215-1314	CACAAGGACTCAAAGGTAATTCAGGTGTCAGGGATGAGCAGACTTTCCTTTTGTATCTGACTGTGGGAACTTGAGAATCTGTCCCGGAACTACAAGTTGG	ENSDARG00000036670	ENSDART00000129643.2:1214	ZGA gene
<i>apoeB</i>	ENSDART00000058965.2	566-665	TACCTGCAAGAGCTGAAGACCATGATGGAGCAGAATGCAGATGACGTGAAGAACCCTGTCGGCACCTACACACGCAAACCTGAAGAAACGCCTGAACAAGG	ENSDARG00000040295	ENSDART00000058965.2:565	ZGA gene
<i>asb11</i>	ENSDART00000079068.2	415-514	CCCGCCCTTGTGAGCCTCATTGACACACAGCTCCGCCACCATCCAGCTCACCTGCTCTGCTCACCTCTGCATGAAGCTGCAAGAGAGGTACACCGG	ENSDARG00000056561	ENSDART00000079068.2:414	ZGA gene
<i>atf4a</i>	ENSDART00000042970.2	496-595	ATCTGGATCTGGACTCTCTCCGTTCCGTTCCGACAGCTGGATCTCCCTCTGGCCCTGGACCTCCGCTTCTGAAGAGATCAAATCGGAGCCTCTCTC	ENSDARG00000039515	ENSDART00000042970.2:495	ZGA gene
<i>atf4b</i>	ENSDART00000055609.2	579-678	GGATTGGATGACAGAACGAATTGATCTGAGTGAGTTGATCTGGAGTCTTTGATAGACTTTATGATTCTGAGGATCCACCCAGTTCTCTGAGGAGCTC	ENSDARG00000038141	ENSDART00000055609.2:578	ZGA gene
<i>blf</i>	ENSDART00000063318.2	1213-1312	CTTTACTTGGGAATCATGCTGAAGAACCACCTGAAAACCTCATTGAGGAGAGCCTCATAAGTGTCCGCTGCGGTAAGGTTTTCCGCTGGCAAAT	ENSDARG00000043126	ENSDART00000063318.2:1212	ZGA gene
<i>bmp2b</i>	ENSDART00000131169.2	1088-1187	CCGAGGAGGCTGAGAGCAACCCGAGGAAGCACGTGAGGGTCAGTCTGTTCCCTTACGCGGATGAGGACTCGTGGGCACAAGCCCGACCTCTGCTGGTAAC	ENSDARG00000041430	ENSDART00000131169.2:1087	ZGA gene
<i>bmp7a</i>	ENSDART00000016472.2	1143-1242	GACTGTTTTCATTTCATAAACCCCTGAAACTGTCCCGAAGCCCTGCTGCGCTCCAACCTCAGCTGCACGGAATCTCAGTTTTGTACTTCGATGACAGCTCC	ENSDARG00000018260	ENSDART00000016472.2:1142	ZGA gene
<i>C22H19orf44</i>	ENSDART00000122324.2	830-929	TGAATGATCTTTTCTGCTGCTCCAGCACATGATTTGAAACACTCTGAGCGAGATGAGTGCAGCATCTGATGATTTCAAACCTGAACGTAATGACACT	ENSDARG00000090673	ENSDART00000122324.2:829	ZGA gene
<i>ccne2</i>	ENSDART00000038155.2	550-649	AGACATTGGCAAAGATCAACTGCAGCTCATCGGCATAACCTCACTCTTCATAGCCTCAAAGATAGAGGAGATTATCCACCAAAGCTCCAAGAGTTTGTCT	ENSDARG00000027918	ENSDART00000038155.2:549	ZGA gene
<i>cebpb</i>	ENSDART00000062702.2	565-664	GACGCGCATAGACCCGTGTTTCAGCCCGACTTTATGGGCAGTTTTGCCAAAAGTAACGGGCGACACGAAGAGACGCCAATGGATGGTCCCGTGGCTAT	ENSDARG00000042725	ENSDART00000062702.2:564	ZGA gene
<i>clDNE</i>	ENSDART00000063320.2	389-488	AGGCTAAAGTGTCCATCGCCAGCGGCGTGATCTTCATCATTGCTGGAGTTCTGGTGTGGTGCCTGTTTGTGGTCCGCCAACACCATCATCAGAGATT	ENSDARG00000043128	ENSDART00000063320.2:388	ZGA gene
<i>ctst3</i>	ENSDART00000065435.2	203-302	CAAAGATTCTCAGAGTGCCTACAGTTCGCAATGGCCAGTACAACAGACAAAGCAATGATGCGTATGTGAGAGGTGTTTCAAAGTACCAAGCTCCAA	ENSDARG00000007795	ENSDART00000065435.2:202	ZGA gene
<i>cxcr4a</i>	ENSDART00000080350.2	387-486	GAGGGTTCATGTGCGTGGCCGTGCATATGATTTACACGGTAAACTTGTACAGCAGCGTCTCATCTCGCTTCATCAGTTTGGACCGGTACCTCGCTGT	ENSDARG00000057633	ENSDART00000080350.2:386	ZGA gene
<i>cxcr4b</i>	ENSDART00000061499.2	1017-1116	GTCAGGTTTCAAGTAACTGCCCCGTAACGCTCTGAGCATCAGCAGTAGATCCAGTCAAGATGCTGACCAAGAAAAGGGGGCCTATATCATCTGTATCTA	ENSDARG00000041959	ENSDART00000061499.2:1016	ZGA gene
<i>depdc7</i>	ENSDART00000077341.2	581-680	CAAAACGGATAAATCTCTGGAGGACGTTTTAGGAAATCTGAACATGAACACAACCATCACTCCGAGATGATGAATCTGGGATTATCACAAGAGTTGATG	ENSDARG00000055043	ENSDART00000077341.2:580	ZGA gene

<i>dup6</i>	ENSDART00000104496.2	1268-1367	TATTGATGAGGCCCGTGGACTGAAGTGTGGCGTGCTTGTTCACTGCCTTGCCAGGCATCAGTCGTTCTGCTACTGTAACAGTGGCGTACCTCATGCAGAAG	ENSDARG00000070914	ENSDART00000104496.2:1267	ZGA gene
<i>etv4</i>	ENSDART00000136212.2	410-509	CAGTTACCCCATGAACCCAGTTCAGGTTCCCTTCCGGCTCGGCAGAGATGTGCCACCATTTCGCTTCCCAAGGCCAGGCCCTGCAGCGCATGCATCCT	ENSDARG00000018303	ENSDART00000136212.2:409	ZGA gene
<i>fam212aa</i>	ENSDART00000124800.2	513-612	TAAAAACATTTCGTGTATCCTCCACTGCATGTCTCCGCACTAACAGCTCTCCAACACCCGAGCACGTCTAAATCCACCTCCGATGCTTGCTTGAAAGT	ENSDARG00000070360	ENSDART00000124800.2:512	ZGA gene
<i>fam46ba</i>	ENSDART00000058424.2	1368-1467	CTACATTGCTCACGTGCAGCCGCTGGTTCACACTGCAGTAGTTCCTATCCGACATGGCTGCCCTGTAACAGTACACAGTGCATCCGTTCTCGTACATC	ENSDARG00000039943	ENSDART00000058424.2:1367	ZGA gene
<i>fgfr4</i>	ENSDART00000100286.2	2383-2482	TGCTGGCTGGAGTTATGGAGTTGAACTGCCTTATGATCCTGATTGGGAGTTTCCAAGAGAGAATTTGACTTTAGGGAAACCGCTTGAGAGGGTTGCTT	ENSDARG00000069105	ENSDART00000100286.2:2382	ZGA gene
<i>flh</i>	ENSDART00000011520.2	299-398	TTCGCGTACAGCCAAAGCATCATGCAAACCTCAGACAGGCTATCCCGTGTCTGCTATCCGCCCTACAACCTCCAACAACATGTCGTGGAGCTGTGTACG	ENSDARG00000021201	ENSDART00000011520.2:298	ZGA gene
<i>foxa3</i>	ENSDART00000010813.2	1616-1715	GACCCTCTACAGCAGGTCTGTCTCAATGCATCCTAATGTGTTTACCAGCCAGTTGAACTCTACAGACTGTAATGGCAGGACATCTTCAACACGGAGCT	ENSDARG00000012788	ENSDART00000010813.2:1615	ZGA gene
<i>foxd5</i>	ENSDART00000062303.2	702-801	CTATGAACATTAATAATCCACGACGCTCCAGAAATCCAGCAAAGGCCGAACACAAAACCCAGAGGTGCTCATTGAGCATTGACAGCATTATGGCCAAATC	ENSDARG00000042485	ENSDART00000062303.2:701	ZGA gene
<i>fr82</i>	ENSDART00000016758.2	1191-1290	ATCAGTAAATGAAGTACCAGTTTACTGTGGAGAATCGCACCAAGGAGAAGACTGCCAGAGCTAAAGAAATTCATACAGTGGACAGTTGCTCCTCTGTA	ENSDARG00000055647	ENSDART00000016758.2:1190	ZGA gene
<i>fzd7a</i>	ENSDART00000084055.2	970-1069	ATTACATTACAGCCAAACCTGGTGGTCAGACCAACCAGCAATTCACATGCCCGCTGCAACTCAAAGTGCCACTTATCTGAAGTACCACCTTATGGGCG	ENSDARG00000060004	ENSDART00000084055.2:969	ZGA gene
<i>gadd45ba</i>	ENSDART00000036939.2	589-688	GTTGCAAAAACCAATGGATTCTTATCTGTCCCTGCAAGAACGCTGAACTATTCGCGATGCTGTTTCTGCAACGAAAGGATGAAAGAGTCATTCTCTGCG	ENSDARG00000027744	ENSDART00000036939.2:588	ZGA gene
<i>gadd45bb</i>	ENSDART00000005382.2	547-646	ATGAGGAGGACGAGAATGATGTTGCGCTTCAGATCCACTTCACGCTCATCCAAGCCTTCTGCTGCGACATCGACATCAACATTGTGCGCGTGTCCGGCAT	ENSDARG00000013576	ENSDART00000005382.2:546	ZGA gene
<i>gata3</i>	ENSDART00000025153.2	914-1013	TTCAGAGGGTAGAGAATGTGTAACCTGCGGGCCACCTCGACTCCTCTGTGGCGGAGGGATGGCACCGGTCACTATTTGTGTAACGCCTGCGGACTTTAC	ENSDARG00000016526	ENSDART00000025153.2:913	ZGA gene
<i>grhl3</i>	ENSDART00000114215.2	1521-1620	AATCTGAGGAAGTATTTGATGCCCTCATGCTGAACACGCCAAACCTCAAGGGCCTTAAAGAAGCGATTCAGAAAAAGTATGGCATGCAAGAAGACACCAT	ENSDARG00000078552	ENSDART00000114215.2:1520	ZGA gene
<i>gsc</i>	ENSDART00000082085.2	471-570	TACAGTTATGACAGCGCCGGCTCTGTGCTTATTTCTCCAGTCCCACATCAAATGATGTCGTACATGAACGTGGGCACCTTGTCCAGAACCGAGCTACAG	ENSDARG00000059073	ENSDART00000082085.2:470	ZGA gene
<i>has2</i>	ENSDART00000053754.2	1632-1731	CACAAGCACCCTGTGGATGACTTACGAGGCCGTACACCCGGCTTCTCCCGTTCTTCTTATCGCCACTGCCATTCAACTGTCTACCAGGGCAGGA	ENSDARG00000036987	ENSDART00000053754.2:1631	ZGA gene
<i>her11</i>	ENSDART00000126216.2	142-241	ATGACGAAGACAGAAGGGATCAAAAAGAAGGCTAAAGCCTGTATAGAGAAGAAAAGGAGAGATCGGATTAACCACAATCTAGACGCATTAAGAGATCTGC	ENSDARG00000002707	ENSDART00000126216.2:141	ZGA gene
<i>her5</i>	ENSDART00000145336.2	457-556	ATGTGAAAACATACACAAATCGCACTCAAGGCAAGTTCAGCTGCTGTCCACACCATCTCGCATAGAACTCAGGTGCATCTCTATGAGGATCCATCACAG	ENSDARG00000008796	ENSDART00000145336.2:456	ZGA gene
<i>hspbl</i>	ENSDART00000149816.1	415-514	AAGATCAGCTCCTGTCTTCTCTGAAGGAGTCTGACTGTTGAAGTCCGCTTCCCAAACCTGCCATCCAGGCCCCAGAAGTTAACATCCCTGTCAACA	ENSDARG00000041065	ENSDART00000149816.1:414	ZGA gene
<i>htafx</i>	ENSDART00000040328.2	431-530	AAATCTGGAAAGAAGGGATCTTCCAGTCACAAGAGTATTAATGTTGAACTGAGCTAATTCATCCAAAGGCCCTTTAAGGGCCACCCAACCTTCTCTGA	ENSDARG00000029406	ENSDART00000040328.2:430	ZGA gene
<i>id1</i>	ENSDART00000059732.2	31-130	ACTCAACAAGCCTTTAAAGGAGTACGAGCACCTCGCTTACGCTATTCCTTCTTACTTACTCGCAAATAGCCAAAATGAAAGTTGTGGGACCTACCTGC	ENSDARG00000040764	ENSDART00000059732.2:30	ZGA gene
<i>ier5</i>	ENSDART00000014330.2	589-688	CATGTTTGTCTTCAAACAGGAAAAGAAGCGCAGAGGAGTCAGAAAGTGCGCATGCGCCTCAAAAAAGGACCAAAGTTGCTTCTCAAACACGAAGGAAG	ENSDARG00000009881	ENSDART00000014330.2:588	ZGA gene
<i>ier5l</i>	ENSDART00000077189.2	815-914	TCCGAGATCGAGGAGGCACCGATTTACGCCGTGCAAAAAGAGCGAAATTCGAGGACTCTCATAACGCGATCACGGAGCCCTTAGACACGTCGAAACATTT	ENSDARG00000054906	ENSDART00000077189.2:814	ZGA gene
<i>iratb</i>	ENSDART00000080576.2	576-675	CCAGAGGAGCATTCTCCTGACCCTGTCATCGGGATGCTTCCATGTTTTTGTGGAATAGCGCCGTCGACCGCACTCCGACCTTCATCATTCCCTTC	ENSDARG00000057813	ENSDART00000080576.2:575	ZGA gene
<i>irx7</i>	ENSDART00000011627.2	712-811	GGGACTCGAGCAGCAAAAAGGAAAGTGACAAGTCTGACACTTTGACCAAAAAGAGAGTCGTATAAACAATCGCTGATGTCCAGAAACCTAAGATCTGGTC	ENSDARG00000002601	ENSDART00000011627.2:711	ZGA gene
<i>isg15</i>	ENSDART00000130554.2	222-321	CATCACAATAATCCCGAACTTCCAGGTGTTGTCGAAGAACGAGAAGGGCCAGGTCAAACTTATGATGTGGACGCCAACGAGACCGTCGATCAGCTC	ENSDARG00000086374	ENSDART00000130554.2:221	ZGA gene
<i>klf17</i>	ENSDART00000056655.2	884-983	ACGGACATTTAATATGTTTACGGAACCACTGCGGGCAAATCACCCGGCCATGCCAGGTGTGATGCTGACTCCACCATCCTCACCTCTCTGGGATTTTT	ENSDARG00000038792	ENSDART00000056655.2:883	ZGA gene
<i>klf2a</i>	ENSDART00000062587.2	550-649	ACTCGGCATGGCAGGCGACTACAGAATGCAAGAGTCCAGAAACATGTACAACCCGACTACATACTCGGTGCTGAGATCAACCCATCACCACTCCACCG	ENSDARG00000042667	ENSDART00000062587.2:549	ZGA gene
<i>klf2b</i>	ENSDART00000149045.1	970-1069	AATGGGGATGCAACCCAGCATGCAGCGGGCTCTTCTACTCCTCCGTCCTCCGTTAGAGCTAATGGAGTCTAAACCAAGCGAGGGCGACGCACCTGG	ENSDARG00000040432	ENSDART00000149045.1:969	ZGA gene
<i>krt18</i>	ENSDART00000137866.2	256-355	CGCCACCTACAGGAGGCTACTGGATGGTGGAGACTTCAAACCTCCAGGATGCTCTTGAAGAGCAGAAGAAGGTCAAAGTGTGACGGTCACGCAGACGCTG	ENSDARG00000018404	ENSDART00000137866.2:255	ZGA gene
<i>krt4</i>	ENSDART00000012644.2	1613-1712	CAGCCGACACAGTTTCAAACCTTCTTACCTGCAACTAGATCCCTTCTGAACCTTCTTACGACTCAAACCATCTATGGTGCTATATTTAGCCAGACAGC	ENSDARG00000017624	ENSDART00000012644.2:1612	ZGA gene
<i>krt5</i>	ENSDART00000129044.2	809-908	GAACCTGGTGGAGGACTTCAAGAACAATATGAAGATGAAATCAACAAGCGTGCCGAGTGGAATAATTTGCTCTGCTGAAGAAGGATGTGATGCT	ENSDARG00000058371	ENSDART00000129044.2:808	ZGA gene
<i>lfng</i>	ENSDART00000028673.2	809-908	AGAAAGACTTGGGGACAACAAAATGAGACCTGTGAATTTCTGTTTGGCACTGGAGGAGCTGTTTCTGTATCAGCCGTGGGCTTGCTTTGAAGATGAGT	ENSDARG00000037879	ENSDART00000028673.2:808	ZGA gene
<i>lrwd1</i>	ENSDART00000050906.2	390-489	GGAAGGATATCAGTTCAACAGCTCATATTCGCCATGGGAGCACTGAGATCCTCAGGAAGCGGGTGATTGGTGTGTGGGAACGAGACTTTAGTCTTCC	ENSDARG00000035147	ENSDART00000050906.2:389	ZGA gene
<i>marcks11a</i>	ENSDART00000056987.2	1040-1139	GGTTTCGTCCGGTCTGGTGTGAGTGTGGTGCACAAACGTTGGAGAGCTTTTTTTTTGTTGTTGGGAATCGGGCCGGAAGTGTCTGTGTTGGATTGGAACG	ENSDARG00000039034	ENSDART00000056987.2:1039	ZGA gene
<i>mcm3</i>	ENSDART00000121535.2	1698-1797	AAAAACAAGGATCGAGTAGTGAGCAAAAGCCTTCATGAGGAAGTACATCCACGTCGCCAAAGCCATTTCTCCAGTTTGGACCAAGATGCAGCCAATCAC	ENSDARG00000090802	ENSDART00000121535.2:1697	ZGA gene
<i>mex3b</i>	ENSDART00000101537.2	1247-1346	CGCCAACGCCAATGGATTTGTCTACAGCGGCGAGGTGATCTCGCCAGATTGCACTGACTTGACCTTCGAGTCGTCGCCAGGATTTGATCCTACTCCTGCG	ENSDARG00000058369	ENSDART00000101537.2:1246	ZGA gene
<i>mid1ip1a</i>	ENSDART00000060150.2	497-596	GAAGTGCACCATGAAGGATCCACATCTACTGCGATATGATGAACTGTTGTGTTGTTCTAAGACGATCTGCTCTGCATTTGTGGAAGAGCCAAAGGGGACT	ENSDARG00000041051	ENSDART00000060150.2:496	ZGA gene
<i>more3b</i>	ENSDART00000074450.2	432-531	TTGGCGTGTACGAAATGGATTCAAATCGGGTCCATGCGCTTGGGAAAAGATGCCATTGTTTACCAAGACTAAAGACACCATGAGTGTGGGGCTCCT	ENSDARG00000043271	ENSDART00000074450.2:431	ZGA gene
<i>MPLKIP</i>	ENSDART00000112014.2	467-566	CCCGGAAGACACTCTGGATATCAGGGTTCACCGCGGACATCCACACCATTTGGTTACGCGCATGGCAGGGATAGAGGGACAAATGATATGGAAAAGTATT	ENSDARG00000078986	ENSDART00000112014.2:466	ZGA gene
<i>mxtx2</i>	ENSDART00000006505.2	717-816	GTTGGATGCCCTAGTAGCATGGAGTCACTTTCAACATCTCCTGCGTCTTCTGATTCTGCATTTGGGACATGGGATTGGAGAACTGCTCTCCATCTGTGC	ENSDARG00000015906	ENSDART00000006505.2:716	ZGA gene
<i>mych</i>	ENSDART00000115049.2	1197-1296	GCCAGACTTGAACAGCTGAAGAGACATTGAGCACCCGGGACTAAACTTTAGCCACTTGATAGTAGTTCGAGTGTCTGGCTGGTTGAGGACTGAAACACAT	ENSDARG00000077473	ENSDART00000115049.2:1196	ZGA gene

<i>neur1b</i>	ENSDART00000088490.2	1314-1413	AAACAAATCAGCATACTGGGCACTTCCCGTGGTTACTCTCCCTCCTGTTTCAGAAACACAGAGGTCCATCTTTAGTGATGCCAGTCACCTCTCTGCCAATC	ENSDARG00000061773	ENSDART00000088490.2:1313	ZGA gene
<i>nmr</i>	ENSDART00000081875.2	401-500	GATATCAGGATGTTTATGGGAAGACACTCCAGATCTCAACAGCCGTAACAGACACCTGGCATGTTAAATTTTCATCTTCTGTGCTGGAGCGATGTGGG	ENSDARG00000058917	ENSDART00000081875.2:400	ZGA gene
<i>polr3gla</i>	ENSDART00000132660.2	713-812	ACTACATTGCGTCTTACTTTGACAACGGAGAGGATTTTGGAGGGGATAGTGATGACAACATGGACGAAGCGGTCTACTAATACATTTCAAGAGGCCTTTT	ENSDARG00000012044	ENSDART00000132660.2:712	ZGA gene
<i>shisha2</i>	ENSDART00000045574.2	399-498	AGTGCGTTCCTGTCGTTTGTGCTGGTCGGTGCATTGTATCTGTCTGCTGCTGCCAGTGTGTGAAGCCAAAGCAAGCGATCATCCAGTGGGACCCTCCG	ENSDARG00000034138	ENSDART00000045574.2:398	ZGA gene
<i>slc25a22</i>	ENSDART00000143900.2	242-341	GTGTTTCCCATCGATTTAGCCAAGACCAGACTCCAGAACCAAAGACAAGGCCAGCAAGTCTACAAGAGCATGATTGACTGCCTCATAAAAACAGTACGAA	ENSDARG00000020893	ENSDART00000143900.2:241	ZGA gene
<i>slc3a2b</i>	ENSDART00000053797.2	1043-1142	AAGTTGCCAAAGCTGTTGAAAGCCTGTATTCCACTTACAATCAGACCCGACTGGCTTGGAAACATCGGTGGACGAATTGCAGGACATCTGGCTTCAGTTGT	ENSDARG00000037012	ENSDART00000053797.2:1042	ZGA gene
<i>snai2</i>	ENSDART00000058571.2	996-1095	AAAAGACGATTTCAAATGCACCTCCCCAGGGTCTGAATGAATCAAATGTTTGTGTTGAGTCAGATTCCAACCAAGATGCTACACGTTGAAGGGATAGTT	ENSDARG00000040046	ENSDART00000058571.2:995	ZGA gene
<i>sox11a</i>	ENSDART00000110040.2	1161-1260	ACTAAATAAGACTATTCCCAAGTAATAACACACACGGGAGAGAGGTATAATGCTCTGTTCTGTACGATTTCTTTCCCTGCCTTCCACTGCTGGTCCAC	ENSDARG00000077811	ENSDART00000110040.2:1160	ZGA gene
<i>sox19a</i>	ENSDART00000114113.2	373-472	CTGTCAACAGCCAACAACAGCAGAGTAGCGATCCTATGGACAAAGTTAAGAGGCCCATGAACGCATTTATGGTGTGGTCTCGGGTTCAGAGGCGCAAAT	ENSDARG00000010770	ENSDART00000114113.2:372	ZGA gene
<i>sox3</i>	ENSDART00000075617.2	973-1072	CCCGGTGGAGACAGCGCCGACCCTCCAGTCTACAGACCAGTCGGTTACACAGCGTTCATCCGCACTATCAAAGCGCAGGGACAGGCGTGAACGGAACGC	ENSDARG00000053569	ENSDART00000075617.2:972	ZGA gene
<i>stm</i>	ENSDART00000105174.2	686-785	AACCGTCAGCCGAGGACCACACAGACGGCAATCACGCTGGAAAAGATTCAACTGATTCAAAGGAATCACCAGACACCCTGACAAGCCAGAAGGACCAGA	ENSDARG00000035694	ENSDART00000105174.2:685	ZGA gene
<i>sult6b1</i>	ENSDART00000130131.2	517-616	CTGGGACAAGTTCTTCTGACTTCATGACTGGTGATGTTAGTTGGGGCTCTTACTTTGATCACGCTCTCGCCTGGGAGAAACGGATAGACGACCCGAAC	ENSDARG00000086826	ENSDART00000130131.2:516	ZGA gene
<i>tbx16</i>	ENSDART00000007090.2	1058-1157	CCCACTGGGATCAGACCATCGAGACGTGTACAGTCCGAGCAGCTCGTTCCAGGACAGAACACATACCAGCCGTACAGATTCACGAATACGGCAAATCC	ENSDARG00000007329	ENSDART00000007090.2:1057	ZGA gene
<i>tp53inp2</i>	ENSDART00000125731.2	405-504	TCTTCCACAACACTTCTCTCGCAAACACCGCATGGTCCTTACCAGCCTGGCCGATGCAACTTTAATCATTAAGATGCAACGAGTACGCAAACGAACAAC	ENSDARG00000088178	ENSDART00000125731.2:404	ZGA gene
<i>tsc22d3</i>	ENSDART00000054115.2	728-827	TACGACCAGTACCAGTGGCCTAGTTCTGTAAAATCCGACAATCTCTTGGGACTAACATGGAAAAGAGAGAGTGATGTAGACGTCCGAGGTTACTGTACAA	ENSDARG00000075666	ENSDART00000054115.2:727	ZGA gene
<i>vent</i>	ENSDART00000017456.2	740-839	ACACATGCAACAAGCCATTTTGGATGGTCAAAAACAGGATCTTATGTGTGCAAGTTGTTACACACACACAACCCGGCGATTTTGCATGCTCAAACATGAT	ENSDARG00000017164	ENSDART00000017456.2:739	ZGA gene
<i>vgl14l</i>	ENSDART00000098925.2	583-682	TTGCGTCTTCTGTCATCAAGGTCAACAAAGCAGGACTGCTGCAATCACTCAACTGCTGTAAGCAAACACAGTTATGACCACGTGCAAGAGCATTTCAG	ENSDARG00000068409	ENSDART00000098925.2:582	ZGA gene
<i>vox</i>	ENSDART00000167949.1	569-668	ACTTGGTTCCAGAACC GAAGGATGAAGCTGAAGCGGAAGTGCAGGAAATGCGCGCGGATTTCTGCTGCCTCAGATGGTACTCCGCCGGTCAATCCCG	ENSDARG00000099761	ENSDART00000167949.1:568	ZGA gene
<i>wnt11</i>	ENSDART00000013590.2	1416-1515	TACTGTGGTAAACTTCACGCGTTGATGGCCTGCCCGGATCGGTTTTGTTTTGGTCAGATGAATTCACGAGCTGGACGTGATGGACATCAGATTAGTTC	ENSDARG00000004256	ENSDART00000013590.2:1415	ZGA gene
<i>yaf2</i>	ENSDART00000080334.2	114-213	GCGAAGCCCTCCTCTGACGACGGCTATTGGGACTGCAGCGTGTGTACATTCAAGAACACCGCCGAAGCGTTCAAATGCATGATGTGCGATGTCAGGAAGG	ENSDARG00000015966	ENSDART00000080334.2:113	ZGA gene
<i>yy1a</i>	ENSDART00000062811.2	1302-1401	CACACATTTTGTGTTGGAATTGAAATGTGAACGAGGAACTGACACCAAATACCCCGTCAAGCATCTCGTGGTATAGACCTGAATTAATAACTTCCCGG	ENSDARG00000042796	ENSDART00000062811.2:1301	ZGA gene
<i>zic2b</i>	ENSDART00000054066.2	1501-1600	GCCGCGCTCAACAGCAGCGGGACAATAGCTTAACGTCCAATTTAACGAGTGGTACGTTAAGGACTCCGCCAAGAACTGCATATCCTAAAATAAAATA	ENSDARG00000037178	ENSDART00000054066.2:1500	ZGA gene
<i>znf113</i>	ENSDART00000150313.1	1322-1421	GCGCCATACAACAGAATTTTGCATGCTCAAACCTTTGTGTGACCGCAGCTTCGGTGTGAGAAGAGTTTCAGTTACTCATCAGAAGATACTAGAAAAATAC	ENSDARG00000096172	ENSDART00000150313.1:1321	ZGA gene

Figure 4—source data 1

**Quantification of histone number by mass spectrometry**

See Materials and Methods for details on calculations

<b>ZV10</b>	<b>Diploid</b>	<b>Nucleosome repeat length</b>	<b>Number of nucleosomes per genome</b>	<b>Number of histones per genome</b>
<b>ZF genome bp</b>				
1,464,443,456	2,928,886,912	187	15,662,497	31,324,994

<b>Developmental stage</b>	<b>Number of histones (MS)</b>				<b>Genomes worth of histones (using H2B levels)</b>
	<b>H3</b>	<b>H4</b>	<b>H2A</b>	<b>H2B</b>	
<b>1-cell</b>	1.45541E+11	2.51709E+11	1.27544E+11	97105215623	3,100
<b>8-cell</b>	2.10123E+11	2.26428E+11	1.54090E+11	1.30134E+11	4,154
<b>64-cell</b>	2.57050E+11	2.79328E+11	1.95743E+11	1.67481E+11	5,347
<b>256-cell</b>	3.79166E+11	3.45319E+11	2.64277E+11	2.34229E+11	7,477
<b>1K</b>	5.58281E+11	4.4761E+11	3.63655E+11	3.38214E+11	10,797
<b>high</b>	5.58765E+11	4.62853E+11	3.73629E+11	3.54292E+11	11,310
<b>oblong</b>	6.17021E+11	5.14486E+11	4.31972E+11	4.20873E+11	13,436
<b>sphere</b>	7.00739E+11	5.62105E+11	4.79085E+11	4.48329E+11	14,312
<b>dome</b>	1.14981E+12	8.90349E+11	7.76771E+11	7.33550E+11	23,417
<b>shield</b>	2.01057E+12	1.37378E+12	1.15772E+12	1.25128E+12	39,945